TopTip American Oriental - China Biotech Aktie mit niedrigem KGV - 500 Beiträge pro Seite

[ProMaiLer]

American Oriental

WKN: 590111
US Symbol: AOB
MK: 147 Mio USD
Kurs: 3,67 USD

Umsatz 02: 10,2 mio usd
Umsatz 03: 20,8 mio usd
Umsatz 04: 31,9 mio usd

Gewinn 02: 1,1 mio usd
Gewinn 03: 4,6 mio usd
Gewinn 04: 7,7 mio usd

Umsatz Q1 05: 9,6 mio usd (+64%)
Umsatz Q2 05: 11,9 mio usd (+98%)

EPS Q1 05: 0,05 usd
EPS Q2 05: 0,08 usd

cash and cash equivalents 30.6.05: 14,9 mio usd

http://www.slyjt.com/aobo/index.htm





Das cinesische unternehmen hat sich auf pflanzliche medikamente und nahrungsergänzungen spezialisiert.

Leider etwas spät der thread (hab das teil schon seit gut 1 usd auf der watchlist ), aber ich denke, auf dem niveau immer noch ein kauf.

aufgrund der quartalszahlen, die man für 2005 abgeliefert hat und dem fakt, dass quartal 3 und 4 besonders stark waren in der vergangenheit, gehe ich konservativ von einem EPS von 0,30 usd für 2005 aus. damit hätten wir auf dem aktuellen kursniveau ein KGV von 12.
und das bei einem wachstum von rund 50%

[WissenMacht]

für mich auch strong buy

[Glück]

Gefällt mir auch sehr gut - danke

[ProMaiLer]

ja, zumal wenn man bedenkt, dass die chinesen ja ihrer traditionellen heilkunde sehr verbunden sind, ein sehr aussichtsreicher wert

[ProMaiLer]

fängt ja gut an für den einstieg

+7%

[Glück]

[posting]17.744.107 von ProMaiLer am 31.08.05 17:03:14[/posting]Bin auch eingestiegen, konnte ich mir durch Deine
tolle Zahlenpräsentation auch nicht verkneifen

[Glück]

Fällt die 4 noch heute

[ProMaiLer]

4,02

hm, solche chancen gibts es ja eigentlich "öfters" mal
ich meine, das wachstumswerte mit einem realen kgv von 3 oder so dahindümpeln

vielleicht sollte ich ja mal nen newszirkel ins leben rufen, in dem alle mitglieder solche chancen posten können

WO ist dazu ja etwas ungeeignet, da es hier zuviel threads zu allen möglichen aktien gibt

was meint ihr?

[Glück]

Ich würde gerne an so einem Zirkel teilnehmen - nur bin
ich aus zeitlichen und ... Gründen en moment nicht unbedingt in einer Spürhundrolle - aber gerne über BM

[ProMaiLer]

ich hätte bei der aktuellen lage noch SARS in den titel schreiben sollen

American Oriental Bioengineering`s Marketing Initiatives Enhance Results of Recently Acquired Heilongjiang Songhuajiang Pharmaceutical Limited; New Subsidiary Generates $2.5 Million in New Purchase Orders


BEIJING--(BUSINESS WIRE)--June 27, 2005--American Oriental Bioengineering, Inc. (OTCBB: AOBO), a rapidly growing Chinese company which produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that recent marketing initiatives for Heilongjiang Songhuajiang Pharmaceutical Limited (HSPL), its recently acquired subsidiary, have generated $2.5 million in new orders. For more than 50 years, HSPL has played a leading role in the Chinese pharmaceutical industry. Its focus on R&D resulted in proprietary products such as Shuanghuanglian Lyophilized Powder Injection. The product is an antiviral medicine and a most highly regarded herbal products approved by the China FDA for the treatment of SARS.

The Company recently held a series of promotional meetings in eight provinces and municipalities throughout China, including Heilongjiang, Hebei, Henan, Anhui, Xingjaing, Hunan, Guangdong, Guangxi, Beijing, Tianjing. In these meetings, AOBO`s technical and sales and marketing staff hosted agencies, distributors and customers to enhance awareness of HSPL`s products. Over 4,150 distributors attended.

"Since acquiring HSPL we have taken several significant initiatives to expand its revenue base," said Tony (Shujun) Liu, AOBO`s Chief Executive Officer. "As a private company, we have begun several marketing programs to capitalize on the extensive investments that HSPL has made in product development. We have also increased our customer base through expanded distribution channels, as demonstrated by the strong attendance at our recent meetings. We believe that HSPL`s unique product line affords AOBO a competitive advantage in the market, and we plan to capitalize on many of its innovative products through further marketing activities in the second half of the year."

[Glück]

Läuft langsam höher, gefällt mir immer besser, findet auch
richtig viel Handel in dem "Ding" statt

[ProMaiLer]

4,15
da kann man nicht meckern

[teerecs]

ich spürte die positive aura dieser aktie und bin auch eingestiegen. danach war ich gleich mal im reformhaus, ein paar pflanzliche produkte kaufen. das wirkt sich dann hoffentlich nicht nur auf die gesundheit aus!

weiß jemand wann neue news, zahlen oder irgendwas kommen soll?

[ProMaiLer]

echt? ich auch, ein leichtes bei den kurssprüngen

[ProMaiLer]

+15% heute schon wieder

[teerecs]

hab leider gerade wenig zeit, um selber wieder zu schauen wie es mit news aussieht.

ich verlass mich die tage mal auf euch, mein geheimer informant ist zur zeit im urlaub auf den bahamas...

[ProMaiLer]

schöne umsätze und ein klassischer durchmarsch

tagesschluss bei 5,08 +21,77%

[ProMaiLer]

$5.65 +0.50 +9.71%

hm, entweder steigen grad alle zocker zu oder fonds kaufen sich ein. es wurden heut 4,3 mio aktien umgesetzt!

[ProMaiLer]

alles roger, die kleine korrektur scheint abgeschlossen, am freitag sind wir nach größeren verlusten sogar noch ins plus gekommen. der RSI ist auch wieder im neutralen bereich

es kann weiter gehen

[ProMaiLer]

nach einer kleinen korrektur gehts weiter steil aufwärts

[trueffelschweinchen]

...es geht weiter gen Norden...wie weit geht die reise wohl noch?
Nach meinen Info`s steht die Aktie auf Alltime High, also existieren auch keine charttechnischen Hürden mehr.
Also: Zurücklehenen und weiterlaufen lassen

[teerecs]

gibt es prognosen oder kursziele?

[HolgiLu]

[posting]18.636.414 von teerecs am 07.11.05 17:26:48[/posting]Bin seit 1,25 Euro dabei und kann nur staunen. Ein Kursziel ist sehr spekulativ, alles ist möglich !!!

[ProMaiLer]

es gibt kein halten mehr! aktuell 7 Dollar!

American Oriental Bioengineering Inc. Applies for Dual Listing on the Archipelago Exchange



HONG KONG--(BUSINESS WIRE)--Nov. 9, 2005--American Oriental Bioengineering Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that it has applied for the dual listing of its common stock on the Archipelago Exchange (ArcaEx), a facility of the Pacific Exchange.

The company`s common stock will not begin trading on the ArcaEx until the company has been approved by the Pacific Stock Exchange and satisfied applicable regulatory requirements. The listing of the company`s common stock on ArcaEx is subject to the company being in compliance with all applicable listing standards on the date its common stock begins trading on the exchange.

The company`s common stock is currently listed on the American Stock Exchange under the symbol "AOB."

[ProMaiLer]

zum 30.9. haben sich übrigens institutionelle mit 1,2 mio altien engagiert!

[ProMaiLer]

American Oriental Bioengineering Announces Opening of First Specialty Store
``Life Peptide`` Opens in Times Square District of Hong Kong; Features AOB`s Soy Bean Peptide Products, Expands Distribution Channel

HONG KONG, Oct 06, 2005 (BUSINESS WIRE) -- American Oriental Bioengineering, Inc. (AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced that on August 12, the Company hosted a grand opening for its proprietary retail specialty store called "Life Peptide," located in the Times Square district of Hong Kong. "Life Peptide" will carry American Oriental Bioengineering soy bean peptide products, intending to respond to the growing demand for these products in new markets, such as Hong Kong. Soybean peptide products are sold over-the-counter remedies intending to promote general overall health for potential users and are utilized as a remedy for a variety of common ailments affecting a person`s overall health and wellbeing.

In addition to being sold at the "Life Peptide" store, the Company`s soy based peptide products will also be offered for sale by other nutraceutical chains commencing on October 15, 2005 including Manning China Resources and Health Plus. The Company expects its soy based peptide products to be on the shelves in approximately 100 stores from such chains.
"This opening of "Life Peptide" exemplifies our strategic business model of increasing the availability of our products to potential customers in under-penetrated and fast growing markets," commented Tony Liu, Chairman and CEO of American Oriental Bioengineering. "This initial move into the Hong Kong market with both our own store and through the distribution channel of other established retailers will increase our customer base with relatively low associated costs and also give us the opportunity to increase sales in the region on a faster basis. We look forward to growing our presence in the region as it becomes a significant contributor to our overall business."

[ProMaiLer]

Chinese herbs
11 Nov 2005

http://www.investor.reuters.com/Article.aspx?docid=8536&targ…

American Oriental Bioengineering is a Lesser Known stock developing drugs from plants.


There are a lot of uses for soybeans. One company found in the Biotechnology & Drugs industry is looking to develop vitamins and drugs from it. This week, the Reuters Select Top Down article series looks at the Healthcare sector. We end this series with a look at American Oriental Bioengineering, Inc. (AOB). AOB caught our attention when it registered recently on the Reuters Select stock screen in the Sentiment category for Lesser Known Stocks.

Continued below

Key Points

AOB develops drugs and vitamins from plants.
The company has been posting revenue and EPS growth rates that easily surpass the Industry averages.
The company has superior profit margins.
AOB`s key product is designed to help treat bed wetting.
AOB is trading at a deep discount to its peers, but it is a very volatile stock.

General Financial Condition

AOB`s revenue and EPS growth rates in the trailing twelve-month (TTM) period (77.84% and 93.01%, respectively) easily outpace the Industry averages (23.73% and 40.26%).

As with the overall Industry, the company`s profit margins have improved of late from their longer-term average. The company has an advantage over its brethren here. AOB`s Operating Profit Margin averaged 21.99% over the last five years, but this improved to 33.87% in the TTM span. Meanwhile, the Industry norm improved from 6.97% to 19.96%. Now, consider the Net Profit Margin. In the TTM time frame, AOB`s figure was 25.33%, while the Industry norm was 13.75%.

AOB`s balance sheet is relatively stronger than the Industry average. The company`s long-term debt to equity ratio is 0.00 against an Industry norm of 0.35; its total debt to equity ratio is 0.13 versus 0.38 averaged by its peers. Further, its interest coverage - a measure of the number of times the company`s interest obligations can be met with operating income - is much higher than the Industry norm (67.12 versus 5.38).

Regarding its valuation, AOB is trading at a considerable discount to its peers. AOB`s price to earnings (P/E, 18.77), P/Sales (4.79), P/Book Value (5.46), and P/Cash Flow (17.15) are all well below the Industry averages (P/E: 45.20; P/Sales: 10.35; P/BV: 6.73; P/CF: 42.00).

Nice Rally

It wasn`t all that long ago that AOB was trading under $2 a share. In early summer, though, a rally erupted that has since pushed it to nearly $6. At present, AOB is trading around $5.50.

So, what`s going on with this company? Well, a lot.

AOB was established in 1970, and it was listed on the OTC bulletin board. In July of this year, it received approval to be listed on the American Stock Exchange.

In a nutshell, the company operates in two areas. One is plant-based pharmaceuticals, and the other is plant-based nutraceuticals. According to the company`s website, AOB operates "through its wholly owned subsidiaries of two pharmaceutical plants, two nutraceutical plant, one R&D institute, and one sales and marketing company."

More specifically, we see that the company is involved in producing and marketing two types of products. The company explains these two product lines as such: "One of these is a line of plant-based pharmaceuticals with more than 80 products featuring Shuanghuanglian Lyophilized Powder Injection and Cease Enuresis Soft Gel; and the other a line of plant based nutraceuticals with over 20 products featuring the double soybean peptide tablets."

The Cease Enuresis Soft Gel is, apparently, the only Chinese FDA-approved prescription medicine that is formulated to help alleviate bed-wetting and incontinence. Strong demand for this product has bolstered the company`s top-line advances in the plant-based pharmaceutical segment.

Enuresis, or bed wetting, is not uncommon in young children, but it is problematic and embarrassing for older suffers. According to the American Academy of Pediatrics (AAP), most children do not become fully toilet trained until they are about 2 to 4 years old, and enuresis affects about 40% of 3-year olds. Also according to the AAP, most children outgrow bed wetting by the time they are in their teens. Yet, there are some adults (about 1%) who suffer from enuresis.

One should also note that AOB`s plant-based pharmaceutical group revenue has also received a nice boost from its acquisition of Heilongjiang Songhuajiang Pharmaceutical Ltd. (HSPL), which has enhanced its product offerings in this area, as well as granted AOB access to new markets.

This is not to reduce the significance of the company`s plant-based nutraceutical product sales. This area has also been faring well, posting double-digit advances.

Going forward, it seems like demand for the company`s products should remain solid, particularly when it comes to the Cease Enuresis Soft Gel product. Another aspect to the company`s growth is its desire to selectively pursue acquisitions. And we can`t forget that AOB recently opened the first of its specialty retail stores. The store, "Life Peptide," opened in the Times Square section of Hong Kong. Also, since mid-October, the company`s products have been available through other nutraceutical chains, including Manning China Resources and Health Plus.

So, what is the price for this growth?

Unfortunately, there aren`t any analysts who provide Reuters with estimates of long-run EPS growth rates, so we can`t calculate any PEG ratios. But, we can compare AOB`s typical valuation metrics to those of its peers. In this regard, we see that AOB is trading at a considerable discount to its peers.

Even though AOB has a price tag that would make many hungry Value investors salivate, it is not well suited for the weak stomached. More specifically, AOB`s beta is much higher than the Industry average.

Beta is a measure of a stock`s sensitivity to fluctuations in the overall market, defined here as the S&P 500 Index. A reading of 1.00 means that the stock moves in lock-step with the market: the market goes up or down by 5%, so does the stock. A beta of less than one means that the stock is less responsive to moves in the overall market, and a beta of zero indicates that the stock`s moves are completely unrelated to those of the market. On the other end of the spectrum, a beta of more than one means that the stock is much more volatile that the overall market. If a stock has a beta of 2.00, this means that the stock has moved effectively double the market: if the market goes up or down by, say, 5%, then the stock has gone up or down by 10%. AOB has a beta of 2.22.

Given the level of volatility inherent to this issue, AOB seems to currently be best suited for risk-tolerant investors looking for exposure to niche segments of the Healthcare sector.

[teerecs]

man da haste ja mal deine freizeit für was nützliches eingesetzt!

da geht noch was bei aob

[ProMaiLer]

es kommt noch besser!

institutionelle haben zum 30.9 sogar 2,24 mio aktien eingekauft!

damit hat sich der anteil institutioneller von 0,00 auf 5,8% erhöht. bin schon auf das kommende quartal gespannt!

werden bei diense kursen demnächst nochmal zuschlagen

[ProMaiLer]

sorry, 4,5% sind es

[ProMaiLer]

so wies ausschaut steigen weitere fonds ein

[amorphis]

Press Release Source: American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. Prices up to $60 Million Private Placement
Wednesday November 23, 2:49 pm ET

HONG KONG--(BUSINESS WIRE)--Nov. 23, 2005--American Oriental Bioengineering Inc. (AMEX: AOB - News), a leading Chinese manufacturer and distributor of pharmaceutical and nutraceutical products, announced today that it is conducting a private offering to accredited investors with respect to an offering of up to 12,500,000 units, each unit consisting of one share of its common stock and three-tenths of a warrant to purchase one share of its common stock, at a price of $4.80 per unit, for anticipated aggregate proceeds of up to approximately $60 million. The proceeds, net of offering fees and expenses, will be used to finance acquisitions and for general corporate purposes.

ADVERTISEMENT
The shares and warrants have not been registered under the Securities Act of 1933, as amended, (the "Securities Act"), or any state securities laws, and unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. American Oriental Bioengineering is obligated to register the shares, including the shares issuable upon exercise of the warrants, for resale on a registration statement to be filed within 45 days of the closing of the transaction and to be effective within 90 days of the closing of the transaction.

After accounting for conversion of the warrants issued pursuant to the transaction, American Oriental Bioengineering will be issuing 17,387,500 shares of its common stock. The company currently has approximately 9,700,000 shares of common stock available for issuance. As a result, the company is required to obtain shareholder approval to amend its certificate of incorporation to increase the number of authorized shares that it is permitted to issue. In addition, the rules of the American Stock Exchange require the company to obtain shareholder approval as a result of the issuance of greater than 20% of its currently outstanding stock at a discount to the current market price. A portion of the proceeds of the offering will be held in escrow until the company obtains the required shareholder approval.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

[trueffelschweinchen]

Ich werd aus der Meldung nicht ganz schlau, kann mir jemand auf die Sprünge helfen?

[ProMaiLer]

naja, kapitalerhöhung für übernahmen und sonstiges in höhe von 60 mio dollar

also ich hab heute nochmal zugeschlagen

klar, einerseits verwässert dass das ergebnis, andererseits fließen der firma 60 mio zu und 2. ist da jemand bereits, 60 mio dollar zu investieren. sicher nicht ohne grund. klar dass man da einen discout gegenüber dem börsenpreis bekommt.

[sirfrancisdrake]

Weiß jemand mehr ?

[amorphis]

da gibts nicht viel zu wissen...chartechnisch angeschlagen...sowie neue aktien im wert von 60 millionen...das übt druck aus...ansonsten gibts keine news...

[teerecs]

das nervt doch... immer wenns blendend läuft werden neue aktien bis zum umfallen ausgegeben...

mir wäre es lieber, die hätten das nicht gemacht

[teerecs]

sehr ruhig geworden hier..

ist noch jemand drin bei aob?

[trueffelschweinchen]

Hallo teerecs,

leider wirklich sehr ruhig geworden bei AOB, die Aktie ist für mich momentan schwer zu beurteilen.
Die Aktie war natürlich schon ziemlich heiss gelaufen, dann hat die Kapitalerhöhung belastet, ohne neue Nachrichten wird sich wohl erst mal nicht viel nach oben bewegen. Bei guten news dürfte es aber durchaus wieder hoch gehen.
Deshalb arbeite ich mit der Drittelstrategie:
Ich habe 1/3 zu 6,00 Euro verkauft, für 1/3 einen SL bei 2,5 Euro gesetzt und 1/3 werde ich auf jeden Fall halten.

[teerecs]

ja ich weiß ja jetzt auch nicht so bei denen...

also ich bleibe noch drin, wenn der kurs sich wenigstens jetzt hält. wenn der gewinn weiter wächst, müssen die ja irgendwann mal wieder steigen.

ich frage mich nur, wie lange die konsolidierung anhält?

[ProMaiLer]

American Oriental Bioengineering, Inc. Closes $60 Million Private Placement



HONG KONG--(BUSINESS WIRE)--Dec. 9, 2005--American Oriental Bioengineering, Inc. (AMEX:AOB), a leading Chinese manufacturer and distributor of pharmaceutical and nutraceutical products, announced today that it has closed its private offering to accredited investors of 12.5 million units at a price of $4.80 per unit, for gross proceeds of $60 million. Each unit consists of one share of common stock, par value $0.001 per share, and three tenths of a warrant to acquire one share of common stock at an exercise price of $6.50 per share. The co-placement agents were CRT Capital Group LLC and Westminster Securities Corp. The proceeds will be used for potential acquisitions and general corporate purposes.

Gross proceeds of approximately $26,527,680, reflecting subscriptions for 5,526,600 units, will continue to remain in escrow, pending (i) the expiration of the requisite waiting period under Rule 14c-2 of the Exchange Act of 1934 with respect to the company`s Information Statement on Schedule 14C filed with the Securities and Exchange Commission on December 7, 2005, (ii) the filing of an amendment to the company`s certificate of incorporation increasing the number of its authorized shares of common stock to 150 million and (iii) the approval of an additional listing application to be filed with the American Stock Exchange with respect to the common stock underlying the units to be issued upon release of the remaining escrowed proceeds.

Tony Liu, Chairman and CEO of American Oriental Bioengineering, commented, "The company plans to use the proceeds for general corporate purposes and seeks to identify accretive acquisition targets within our industry to diversify our product line, accelerate our growth and more effectively leverage our distribution channels."

The shares and warrants have not been registered under the Securities Act of 1933, as amended, (the "Securities Act"), or any state securities laws, and unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. American Oriental Bioengineering has entered into a registration rights agreement obligating it to file a registration statement with the Securities and Exchange Commission registering the shares, including the shares exercisable upon exercise of the warrants, within 45 days from the closing, or January 22, 2006.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities.

[ProMaiLer]

so, die dinger sind an den mann gebracht und jetzt gehts wieder aufwärts

[ProMaiLer]

American Oriental Bioengineering Inc. Options to Trade on Chicago Board Options Exchange (CBOE)



HONG KONG--(BUSINESS WIRE)--Dec. 14, 2005--American Oriental Bioengineering Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that on Thursday, Dec. 1, 2005, options on the company`s common stock began trading on the Chicago Board Options Exchange ("CBOE"). The CBOE is the world`s largest options marketplace.

American Oriental Bioengineering options trade on the January expiration cycle with exercise limits set at 25,000 contracts on each side. The Designated Primary Market Maker for AOB is Susquehanna Investment Group.

In the last six months, AOBO has taken several steps to improve the visibility of the company`s stock. On July 18, 2005, the company`s common stock began trading on the American Stock Exchange. On Oct. 26, 2005, options on the company`s common stock started trading on Pacific Exchange and most recently on Nov. 11, 2005, the company`s common stock was approved for dual listing on the Archipelago Exchange ("ArcaEx"), a facility of the Pacific Exchange, and began trading on ArcaEx on Nov. 11, 2005.

"We are pleased to have our options traded on the largest options marketplace, the Chicago Board Options Exchange, and we believe this is another important event as we continue to improve the visibility and liquidity of our stock," commented Tony Liu, chairman and CEO of American Oriental Bioengineering.

[willmoos]

hi!
wann kommt denn der nächste Quartalsbericht?

wm

[trueffelschweinchen]

Hat schon jemand was über die Quartals- bzw. Jahreszahlen gehört?

[nevertheless]

Ein genaues Datum für die nächsten Zahlen ist nicht bekannt - vermutlich werden die Zahlen Mitte Februar veröffentlicht.

Bin bei 1,90 USD eingestiegen und sehe weiteres Aufwärtspotential. Auch wenn die jüngste Kapialerhöhung um 60 Mio. USD für Unmut sorgte. Immerhin düfte AOB jetzt rund 80 Mio. USD auf der hohen Kante haben (keine Verschuldung). Damit soll nach Meinung des Vorstandes das hohe Wachstum des Unternehmens sowie weitere Akquisitionen finanziert werden. Man darf gespannt sein, welche Akquisitionen American Oriental tätig wird.

Im Jahr 2006 gehe ich von einer Fortsetzung des Wachstums aus. Ohne neue Akquisitionen könnte der Umsatz von rund 53 Mio. USD in 2005 - konservativ geschätzt - auf 80 – 85 Mio. USD ansteigen. Der Gewinn nach Steuern könnte sich von 15 Mio. USD auf etwa 23 Mio.- 25 Mio. USD bzw. ca. 0,40 Cents je Aktie erhöhen. Dies würde einem Kurs-Gewinn-Verhältnis von nur 13 entsprechen. Unter fundamentalen Aspekten ist American Oriental nach wie vor unter-bewertet.

Weiter Fantasie düfte der Wert durch die Tochter HSPL bekommen. HSPL verfügt mit Shuanghuanglian Lyophilized Powder ein in China zugelassenes Mittel gegen SARS.

[sirfrancisdrake]

Hallöchen,
gibt es irgendwelche Neuigkeiten oder normale Kursbewegung?
Bitte um Antwort

[trueffelschweinchen]

Hier sind endlich die Zahlen von AOB für 2005:
Insgesamt kann sich das durchaus sehen lassen, das Wachstum ist immer noch recht dynamisch. Wenn keinen weiteren KE kommen, hat AOB auf jeden Fall Potential, ist außerdem charttechnisch bei ca. 3,80 Euro gut abgesichert. Nach der Konsolidierung könnte die Aktie bei einem Ausbruch auch wieder kräftig gen Norden laufen, ich werde jedenfalls warten, in der Ruhe liegt die Kraft


American Oriental Posts Higher 4Q Profit
Friday March 31, 9:13 am ET
American Oriental Bioengineering 4Q Profit Rises 51 Percent on Strong Sales; Shares Up in Premarket


NEW YORK (AP) -- Chinese biotechnology company American Oriental Bioengineering Inc. reported fourth-quarter earnings rose 51 percent on strong sales of pharmaceutical and nutritional products.
Net income for the quarter ended Dec. 31 was $4.2 million, or 8 cents per share, versus $2.8 million, or 8 cents per share, in the 2004 period. The company issued 17.6 million additional shares during the year.

Quarterly revenue rose 56 percent to $19.8 million, compared with $12.7 million a year earlier. The company's pharmaceutical product line, which accounts for 61 percent of the company's sales, had $12.1 million in sales, an increase of 49 percent.

For the full year, revenue surged 71 percent to $54.7 million, versus $32 million in 2004. Net income was $13.4 million, a 72 percent increase from 2004.

American Oriental Bioengineering, which went public in 2003, develops and markets medicinal products such as health drinks and gels, primarily in China. The company has a market capitalization of $260.6 million.

Shares of the company rose 37 cents, or 7 percent, to $5.60 in premarket electronic trading. The company's shares have traded in a range of $1.02 and $7.68 in the past year.

[berndh70]

Auch wenn´s hier ruhiger geworden ist arbeiten die Herren bei AOB stetig weiter:

American Oriental Bioengineering, Inc. Announces Acquisition Of Guangxi Lingfeng Pharmaceutical Company
4/18/2006

American Oriental Bioengineering, Inc., a company that produces and distributes a broad range of pharmaceutical and nutraceutical products throughout China, today announced the closing of the acquisition of Guangxi Lingfeng Pharmaceutical Company Limited (GLP), a pharmaceutical company, organized under the laws of China, specializing in manufacturing and distribution of plant-based medicines in China. GLP, based in Hezhou City, Guangxi, China, was founded in 1975. Over the past 30 years, GLP has developed a valuable product portfolio aimed at pediatrics, gynecopathy and the treatment of digestive and respiratory system illnesses.

Pursuant to the agreement, AOB acquired 100% ownership of GLP for a total consideration equal to 2.5 times GLP's prior fiscal year revenue. Based on unaudited financial statements consistent with Chinese GAAP, GLP generated revenue of over $10 million USD with positive net income for the year ended December 31, 2005. The purchase price is approximately $25 million, which consists of approximately $20 million USD in cash (subject to adjustments based on completion of US GAAP audits on GLP financial statements) and 1,200,000 shares of restricted common stock of AOB. Subsequent to the closing today, audited financials of GLP will be filed with the Securities and Exchange Commission within the time frame as stipulated by SEC rules.

AOB expects that the acquisition of GLP will extend AOB's product line into the area of women's health and create synergies between GLP's Jinji Series of drugs aimed to treat gynecological inflammations, such as endometritis, annexitis, and AOB's Cease Enuresis product line for the treatment of bedwetting and nighttime urination, primarily targeted at pregnant and post-pregnant women.

GLP has a portfolio of 70 products and operates a distribution network based in Beijing, which extends across China, with a particularly strong presence in Southern China where AOB has yet to establish a significant distribution network. The production facilities of GLP maintain a Good Manufacturing Practices (GMP) certificate as awarded by the Chinese Government and can produce a broad spectrum of delivery specifications, such as capsules, troches, granules, pills, syrups and tinctures.

Tony Liu, Chairman and Chief Executive Officer of AOB said, "GLP is an established and proven manufacturer of plant-based pharmaceuticals with a valuable brand, an extensive distribution network and the opportunity to capitalize on their under-utilized product portfolio. The Jinji Series of gynecological products will contribute to AOB's position in women's health products, which is a large and rapidly growing market in China."

Mr. Liu continued, "AOB expects to leverage GLP's proprietary product portfolio to improve the breadth of our product offerings. GLP also delivers strength in distribution in southern China where AOB has historically been under-represented. We are extremely excited about this acquisition and the financial and strategic value it represents. We believe, similar to the HSPL acquisition in 2004, GLP possesses both immediate value and tremendous upside potential for AOB and its shareholders."

[trueffelschweinchen]

Langsam kommt ja wieder Schwung in die Aktie, Freitag 9% plus in Amerika.
Ist eigentlich sonst noch jemand investiert in AOB?

[Bachalor]

hallo

ich hatte die aktie im mai 2005 per e-mail 1800 usern empfohlen
da gab ich folgende meldungen dazu raus


Über Amerikanische Orientalische Biotechnik Inc..
American Oriental Bioengineering, Inc. (AOBO) ist eine führende chinesische Biotechnologiefirma, die eigene Prozesse für Soyabohneproteinpeptid leistungsfähiger produzieren als traditionelle extrahierende Techniken verwendet. Diese Techniken werden verwendet, um die zusätzlichen und medizinischen Produkte herzustellen und zu formulieren. Soyabohnepeptide werden allgemein in der allgemeinen Nahrung, in den Gesundheit Nahrungsmitteln und in der Medizin, unter anderen Anwendungen verwendet. AOBO produziert auch Aufhören-Cease-Enuresisweiches Gel, den einzigen chinesischen FDA-ANERKANNTEN ersten Grad, Verordnungmedizin, die besonders formuliert wird, um zu helfen, Bett-Bed-wetting und incontinence zu vermindern. Die Firma ist ein führender Produzent der Produkte in den nutriceuticals und in den Produktbereichen in China. Zu mehr Information Besuch http://www.bioaobo.com.
Diese Nachrichten Freigabe enthält das Vorwärts-Schauen von von Aussagen, wie durch die private Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995 definiert. Vorwärts-schauend schließen Aussagen die Aussagen hinsichtlich sind der Pläne, Zielsetzungen, Ziele, Strategien, zukünftige Fälle oder Leistung und zugrundeliegende Annahmen und andere Aussagen ein, die anders als Aussagen über historische Tatsachen sind. Diese Aussagen sind abhängig von Ungewißheiten und Gefahren einschließlich, aber begrenzt nicht auf, verlangen Produkt und Service und Annahme, Änderungen in der Technologie, in der Wirtschaftslage, in der Auswirkung der Konkurrenz und der Preiskalkulation, in der Regierung Regelung und in anderen Gefahren definiert in diesem Dokument und in den Aussagen eingeordnet von Zeit zu Zeit mit der Sicherheiten und Austausch-Kommission. Alle in Zusammenhang mit dem Erwerb angeregt eingeordnet zu werden Leser werden, das 8-K zu wiederholen, der oben besprochen wird, der umreißgefahr Faktoren einschließlich Schuldverpflichtungen, Abkommenbezeichnungen und andere relevante Einzelteile. Durch all diese Vorwärts-schauende Aussagen, ob geschrieben oder mündlich und ob gebildet oder im Namen der Firmen, ausdrücklich durch die Vorsichtsaussagen und irgendwelche anderen Vorsichtsaussagen qualifiziert werden, die die Vorwärts-schauenden Aussagen begleiten können. Zusätzlich dementieren die Firmen jede mögliche Verpflichtung, irgendwelche Vorwärts-schauenden Aussagen zu aktualisieren, um Fälle oder Umstände nach dem Datum hiervon zu reflektieren.
QUELLE: Amerikanische Orientalische Biotechnik, Inc..
Amerika Oriental Bioengineering Inc. Lilie-Li,
917-838-0689 (US.) oder [phone] (China)
[e-mail] oder Investoren: CEOcast, Inc. für
amerikanische orientalische Biotechnik ED Lewis, 212-732-4300
[e-mail]

Copyright-Geschäft Leitung 2005

[Bachalor]

Amerikanische orientalische Biotechnik wählt Eileen Brody zu seiner Direktion
MITTWOCH, JUNI 22, 2005 1:11 P.M.
- BusinessWire
Hong-Kong, Jun 22, 2005 (GESCHÄFT LEITUNG) -- American Oriental Bioengineering Inc., (AOBO) , eine schnell wachsende chinesische Firma, die eine ausgedehnte Strecke der pharmazeutischen und nutraceutical Produkte produziert und verteilt, heute verkündet, daß sie Eileen Brody zu seiner Direktion gewählt hat. Ms Brody wird der dritte unabhängige Direktor für die Firma, die die amerikanische Börsenzulassungsbestimmung für Brettunabhängigkeit trifft. Sie dient auch als der Vorsitzende des Bilanz-Ausschusses der Firma. Ms Brody ist ein Erfahrung älterer Kleinhauptleiter, mit 21 Jahren Erfahrung helfendem Einzelhändlerzunahmewachstum und -rentabilität.
Von waren 1997 bis 2004, Ms Brody Vizepräsident des Verkaufens und der allgemeine verkaufende Manager für Childrenwears Carters Kleinabteilung, eine Abteilung William Carter Company. Dort war sie verantwortlich für das verkaufende P&L für die allgemein Kette mit 175 Speichern. Sie half Leitung eine Umkehrbemühung, die Rekordverkäufe und Rentabilität für sieben nachfolgende Jahre produzierte. Während dort, sie die Firma in seinem erfolgreiche New York Börse-Initiale allgemeinen Antrag unterstützte.
"ich freue mich, Eileen zu unserer Direktion zu begrüßen,", sagte Tony (Shujun) Liu, Vorsitzenden und Generaldirektor der amerikanischen orientalischen Biotechnik, Inc.. "ihre nachgewiesene Schiene Aufzeichnung, wenn sie anderen auftauchenden Firmen hilft, wachsen sollte unschaetzbares prüfen, während wir fortfahren, Erwerb organisch und über zu erweitern. AOBO wird gut in Position gebracht, um fortzufahren, starkes Einkommen zu erzeugen und Einkommenwachstum, als Erwerb wie Heilongjiang Qitai pharmazeutisches begrenztes, ein führender chinesischer Verteiler der pharmazeutischer Produkte und Heilongjiang Songhuajiang pharmazeutische Co., Ltd., die weithin bekannte Produktprodukte in China für fünfzig Jahre gebildet hat, beglückwünscht unsere schnell wachsenden vorhandenen Geschäfte. Wir freuen, Erfahrung und Sachkenntnis Eileens zu verwenden, um AOBO Treffen zukünftig zu helfen seine konkurrenzfähigen Wachstumzielsetzungen."
"ich werde geehrt, zur Direktion für die amerikanische orientalische enthaltene worden Biotechnik gewählt zu werden," sagte Ms Brody. "die Firma ist an einem wundervoll günstigen kritischen Augenblick, zum des drastischen Wachstums innerhalb Chinas zu erfahren und in neue Grenzen um die Welt zu erweitern. Mit dem starken strategischen Anblick und nachgewiesenen der Führung der Firma ist die Zukunft sehr hell. Ich freue, meine Sachkenntnis vielen Facetten des Geschäfts während dieser aufregenden Zeit in seiner Geschichte hinzuzufügen."
Vor dem Verbinden Carters, war Ms Brody der Direktor der strategischen Planung für Speicher Bobs, eine Abteilung von Melville Corporation. Dort führte sie eine strategische Projektmannschaft, die Umdrehung das Sinken der Firma vergleichbar die gleichen Speicherverkäufe in Wachstum durch erhöhte Verkaufen und Marketing-Strategien half. Vorher verbrachte sie drei Jahre bei der Firma als Direktor der Waren-Planung, der Verteilung und der Anreicherung, Portion, um neue Speicher zu öffnen und Verhältnisse zu den Teilhabern zu verbessern. Sie hielt auch verschiedene andere Betriebe und Managementrollen während ihrer fünf Jahre mit der Firma.
Von 1983 bis 1990 war sie ein älterer Manager und ein CPA an der Wirtschaftsprüfungsfirma des KPGM Torfs Marwick. Ms Brody empfing ihren Nichtgraduierten und MBA Grad von der Schritt-Universität und einen zweiten MBA von der Harvard graduierten Schule des Geschäfts. Sie empfing den Fitzie Grundlage Preis 1991, wo sie von der Harvard Wirtschaftsschule und vom Fitzie Überwachungsausschuß als die HBS Frau gewählt wurde, die gut mustergültige Führung, akademische hervorragende Leistung und Verpflichtung zur Gemeinschaft demonstriert.

[Bachalor]

Amerikanische orientalische Biotechnik-Listensatz-erstes Viertel-Resultate für 2005
MONTAG, MAI 16, 2005 9:02 MORGENS
- BusinessWire
Hong-Kong, Mai 16, 2005 (GESCHÄFT LEITUNG) -- Amerika Oriental Bioengineering Inc., (AOBO) , eine schnell wachsende chinesische Firma, die eine ausgedehnte Strecke der pharmazeutischen und nutriceutical Produkte produziert und verteilt, verkündetes heute Aufzeichnung erstes Viertel resultiert während der beendeten Periode März, 31, 2005. Die Firma berichtete über Einkommen von $9.65 Million, ein Einkommen 2004 des ersten Viertels des Überschusses mit 63.4% Zunahmen von $5.91 Million. Amerikanisches orientalisches hatte Betriebseinkommen von $3.02 Million, eine Zunahme des Betriebseinkommens von 91.1% Überschuß für das 2004 erste Viertel von $1.58 Million. Amerikanisches orientalisches erzeugtes Reineinkommen von $2.18 Million im gegenwärtigen Viertel oder $0.05 pro verdünnten Anteil, eine Zunahme von 69.2% verglichen bis $1.26 Million oder $0.04 pro verdünnten Anteil für dasselbe vierteln letztes Jahr.
Die Firma beendete das Viertel mit $12.2 Million im Bargeld und Bargeldäquivalenten, die stärkste Kassenposition in seiner Geschichte. Billigkeit des Aktionärs AOBOs erhöhte sich bis $35.3 Million, sein höchstes Niveau überhaupt.
AOBOs Resultate des ersten Viertels zeigten, daß der Erwerb von Heilongjiang Songhuajiang pharmazeutischem begrenztem ("HSPL") erheblich zum Einkommen und zum Einkommen beigetragen hat. Durch diesen Erwerb bietet AOBO jetzt eine ausgedehntere Strecke der medizinischen Produkte in China, wie Shuanghuanglian lyophilisierter Puder-Einspritzung an, die im Markt für rüber 15 Jahre gewesen ist. Das Produkt ist eine wichtige Antivirenmedizin und hat gewordenes der in hohem Grade betrachteten Kräuterprodukte, die durch die Regierung bestätigt werden.
"wir fahren fort, unsere Produktserien und Verteilung Fähigkeiten schnell zu wachsen, organisch und durch Erwerb,", sagte Tony (Shujun) Liu, Vorsitzenden und Generaldirektor der amerikanischen orientalischen Biotechnik, Inc.. "vor kurzem, nahmen wir an einem Absichtsschreiben teil, um Heilongjiang Qitai pharmazeutisches begrenztes ("HQPL"), ein führender chinesischer Verteiler zu erwerben der pharmazeutischer Produkte. Die Verhandlung befähigt uns zum ersten Mal, unsere Produkte in China wegen des starken Verteilungsnetzes HQPLs zu verteilen Groß- und Kleinhandel, das als Katalysator für zukünftiges Wachstum dienen sollte. Wir glauben, daß wir ideal in Position gebracht werden, um fortzufahren, Einkommen und Einkommen schnell zu erhöhen."

[Bachalor]

Marketing-Initiativen der amerikanischen orientalischen Biotechnik erhöhen Resultate vor kurzem erworbenen Heilongjiang Songhuajiang pharmazeutischen begrenzten; Neue Tochtergesellschaft erzeugt $2.5 Million in den neuen Kaufaufträgen
MONTAG, JUNI 27, 2005 8:01 MORGENS

BEIJING, Jun 27, 2005 (GESCHÄFT LEITUNG) -- Amerikanische Orientalische Biotechnik, Inc.. (AOBO) , eine schnell wachsende chinesische Firma, die eine ausgedehnte Strecke der pharmazeutischen und nutraceutical Produkte produziert und verteilt, heute verkündet, daß neue Marketing-Initiativen für Heilongjiang Songhuajiang pharmazeutisches begrenztes (HSPL), seine vor kurzem erworbene Tochtergesellschaft, $2.5 Million in den neuen Aufträgen erzeugt haben. Für mehr als 50 Jahre hat HSPL eine führende Rolle in der chinesischen pharmazeutischen Industrie gespielt. Sein Fokus auf R&D ergab eigene Produkte wie Shuanghuanglian lyophilisierte Puder-Einspritzung. Das Produkt ist eine Antivirenmedizin und die in hohem Grade betrachteten Kräuterprodukte, die durch die China FDA für die Behandlung von SARS genehmigt werden.
Die Firma hielt vor kurzem eine Reihe fördernde Sitzungen in acht Provinzen und Stadtbezirke in China, einschließlich Heilongjiang, Hebei, Henan, Anhui, Xingjaing, Hunan, Guangdong, Guangxi, Beijing, Tianjing ab. In diesen Sitzungen, bewirteten technischen AOBOs und der Verkäufe und der Marketing-Belegschaft Agenturen, Verteiler und Kunden, um Bewußtsein von Produkten HSPLs zu erhöhen. Über 4.150 Verteilern gesorgt.
", seit dem Erwerben von von HSPL, haben wir einige bedeutende Initiativen genommen, um seine Einkommen Unterseite zu erweitern,", sagte Tony (Shujun) Liu, Generaldirektor AOBOs. "als Privatunternehmen, haben wir einige Absatzprogramme angefangen, um auf den umfangreichen Investitionen gross zu schreiben, die HSPL in der Produktentwicklung gebildet hat. Wir haben auch unseren Kundenbestand durch erweiterte Vertriebswege erhöht, wie durch die starke Anwesenheit bei unseren kürzlich stattgefundenen Treffen demonstriert. Wir glauben, daß einzigartige Produktserie HSPLs AOBO ein Wettbewerbsvorteil im Markt sich leistet, und wir planen, auf vielen seiner erfinderischen Produkte durch weitere Marketing-Tätigkeiten in der zweiten Jahreshälfte gross zu schreiben."

[Bachalor]

wir erstellen ab und an e-mails,wo wir dann verschicken



wie entsteht eine e-mail

es gibt unendlich viele aktien,so das sie nie jemand auch nur ansatzweise
überblicken kann.
bekomme ich nun einen aktiennamen öfters geschickt,oder lese ihn
öfters,machen wir uns mal gedanken.
angenommen es war wie bei primacom,nur als beispiel.
primacom ist mit kabel usw tätig.
dann schaue ich wer arbeitet .z.b bei telekom firmen und bereichen,wo dazu
gehören.
dann kommen 2 user aus fonds dazu(die durchsuchen die zahlen,bilanzenm sind
ganz anders ausgerüstet wie normale user)
dazu kamen 2 anwälte für die sehr heikelen verträge der firma,wo im
wirtschaftsrecht tätig sind.
so arbeiteten etwa 10-12 user daran mit.
dann suche ich einen jungen hungrigen user aus,der aus allen fakten eine
e-mail erstellt.
diese e-mail geht dann erst an alle,wo an dieser mail mitgearbeitet haben
zur kontrolle.
unsere arbeit wird vor dem verschicken darin belohnt,daß wir wahrscheinlich
dann einen günstigeren kk haben wie die anderen.

bei aktien mit hohem volumen(z.b gzfx) eröffnen wir ca 2-4 tage später ein
neuer thread
z.b bei mologen,wo es wenig aktien gibt,würden wir ca 2 wochen warten,denn
es bringt uns auf dauer nichts,wenn wir den kurs hochtreiben durch eigene
käufe und dann alle im minus landen.
wir verschicken nur werte auf lannnnnge sicht.
bisher hatten wir sehr viel glück!!dabei
sicher werden wir auch nieten ziehen,aber ich bilde mir folgendes ein.
lasse ich eine aktie von einigen usern,unabhängig voneinander
überprüfen,bekommt man
1.viel mehr material
2.verschieden ansichten
3.einen viel besseren überblick
dann schauen 3-4 leute nach den firmen wo auch in diesem bereich tätig sind.


wir überprüfen auch sehr viele firmen,wo uns das risiko einfach zu groß
erscheint,es den leuten zu sagen,
so war viel arbeit auch für die katz.

jeder sollte sich vor einer investiton selber gedanken machen,denn wir
verschicken mails,wo keine kaufempfehlungen sind.
sie muss wenn möglich alle risiken erhalten,denn ich will das mit den usern
sehr lange machen und das geht nur mit vertrauen.
viele versuchen dies auszunutzen,indem sie mir ihre depotleichen
unterschieben wollen.
ich lasse alles vorm verschicken prüfen und habe auch schon sehr viele
bekannte user bei Wo von meiner liste rausgeschmiessen


ganz einfach
ich persönlich organisiere das,nur ich kenne von vielen ihren job.
ich alleine hätte an der börse absolut keine chance,daher mache ich das.

ich bekomme einige börsenzeitschriften zugesand und bin der meinung
diese leben alle davon,was die user auf wo herrausfinden
Wo user sind besser wie alle pusher zeitschriften,das heisst es zu bündeln
und zu hoffen,daß die leute investiert sind,bevor frick und konsorten ihr
spiel treiben.
es ist viel glück und sehr schwierig.




Bachalor

[Bachalor]

sorry


e-mail war später
kurz vorm wechsel an die amex,bei ca 1.80$

[trueffelschweinchen]

Die Quartalszahlen sind sehr gut ausgefallen, sowohl Umsatz als auch Gewinnsteigerung sind recht beeindruckend.
Die Aktie ist nach einer langen und gesunden Konsolidierung wieder kraftvoll auf dem Weh nach oben, heute wieder +10% in Amerika.



First Quarter 2006 Highlights:



-- Receipt of the Second Tranche of Proceeds in Connection with the December 2005 private placement



-- Operating margins expand to 33.4%, an improvement of over 2.0% versus 1Q 2005



-- Subsequent to the close of the First Quarter, Company announces the acquisition of GLP



American Oriental Bioengineering, Inc. (AMEX:AOB), an emerging Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the first quarter ending March 31, 2006.

Key Financial Indicators
(All numbers in thousands, except per-share amounts in USD) Q1 2006 Q1 2005 Percentage Change
Revenues $ 19,087 $ 9,653 97.7%
Cost of goods sold $ 6,509 $ 3,628 79.4%
Gross Profit $ 12,577 $ 6,025 108.8%
Total Operating Expenses $ 6,194 $ 3,000 106.5%
Income from operations $ 6,383 $ 3,025 111.0%
Net Income $ 4,917 $ 2,183 125.2%
EPS -- Fully Diluted $ 0.08 $ 0.05 60.0%
Diluted Shares 61.3M 42.7M 43.6%




The US dollar amounts are calculated based on the average conversion rate of US $1 to RMB 8.0436 for the first quarter of 2006 and US $1 to RMB 8.3 for the first quarter of 2005.



First Quarter 2006 Financial Results:



For the first quarter, the Company reported revenues of $19.1 million, an increase of 97.7 percent compared to the $9.7 million reported in the first quarter last year and down 3.5 percent compared to the $19.8 million reported in the fourth quarter of 2005. The increase in revenue as compared to the first quarter of last year is attributable to growth in both the Company's Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) products. During the first quarter of 2006, sales of PBP products increased approximately $6.2 million, or 102.8 percent compared to the same period in 2005. PBP revenues were driven by a 137.9 percent increase in Cease Enuresis Soft Gel and Patch sales and a 101.6 percent increase in Shuanghuanlian Injection Powder sales. PBP revenue growth was also driven by continued strength in Double Ginseng Grain product sales, which increased 57.6 percent from the same period of last year. During the first quarter of 2006, PBN sales increased by $3.3 million or 89.4 percent compared to the same period last year as the Company continued to improve its marketing efforts geared towards educating consumers about the benefits of soy-based peptide products. PBN revenues were driven by a 122.9 percent increase in Soy Peptide Tablets and a 116.2 percent increase in Vitamate Oral Liquid sales.

On a sequential basis PBP revenue increased by 0.4 percent while PBN revenue decreased by 9.6 percent. The overall revenue decline on a sequential basis was due to seasonality, which the Company has experienced in the past, as the fourth quarter is traditionally strongest of the year. The Company's 3.5 percent sequential revenue decline in the first quarter of 2006 compares favorably to the 23.6 percent sequential decline in the first quarter of 2005.

Cost of goods sold were $6.5 million, an increase of 79.4 percent compared to the $3.6 million reported during the first quarter of 2005, resulting in a gross margin of 65.9 percent for the first quarter compared to 62.4 percent for the comparable period last year and 65.2 percent during the fourth quarter of 2005. Gross margins improved in the first quarter as the Company yielded higher efficiencies in its manufacturing processes, particularly versus the year-ago period as further improvements were made on the integration of HSPL.

Selling and marketing expenses increased 159.6 percent to $1.7 million. Advertising expenses increased 173.0 percent to $2.2 million, both compared to the first quarter of last year. Total operating expenses were $6.2 million, an increase of 106.5 percent compared to $3.0 million reported for the same period last year as the Company increased expenses to support operational growth.

Operating income increased to $6.4 million, up 111.0 percent from $3.0 million in the year-ago quarter. Operating margins were 33.4 percent, which improved 2.1 percent from 31.3 in the first quarter of 2005 and up 2.0 percent from 31.4 percent in the fourth quarter 2005. The Company continues to seek opportunities to rationalize costs and reduce inefficiencies to drive greater profitability.

The Company had an effective income tax rate during the quarter of 23.9 percent compared to 25.6 percent last year. This tax is in addition to the Value Added Tax (VAT) of 17.0 percent deducted from the Company's gross revenues each quarter. Net income increased 125.2 percent to $4.9 million or $0.08 per fully diluted share versus net income of $2.2 million or $0.05 per fully diluted share in the same period last year. Fully diluted earnings per share increased 60.0 percent as compared to last year and were flat sequentially despite a 43.6 percent and 18.8 percent increase in shares utilized in this calculation relative to the first quarter of 2005 and the fourth quarter of 2005, respectively.

Commenting on the first quarter of 2006, Mr. Tony Liu, Chairman and CEO of AOB, said, "We are very pleased to report a solid first quarter which resulted in strong revenue and earnings despite what is historically a weaker seasonal quarter. The Company experienced strength across all product lines which reflects the success of our efforts to continue to increase brand awareness and further penetrate underserved and rapidly growing markets throughout China."



Balance Sheet



The Company completed the quarter with $80.9 million in cash and cash equivalents. Cash and cash equivalents increased from $57.5 million during the fourth quarter of 2005 primarily as a result of $3.9 million in positive cash flow from operations and the receipt on January 23, 2006, of the second tranche of net cash proceeds of $25.0 million in connection with the $60.0 million private placement effected in December 2005. Short-term debt totaled $3.7 million and was down $1.4 million versus the year-ago period and unchanged from the fourth quarter of last year. Inventory increased 4.5 percent and 64.5 percent from the first quarter of 2005 and fourth quarter of 2005 respectively to $8.1 million. The increase in inventory was below that of overall sales growth for the first quarter with the increase necessary to support the Company's future growth. The Company continues to have excellent quality receivables with overall Days Sales Outstanding (DSO) unchanged from last year at 45 days. As of March 31, 2006, the Company had a current ratio of 11.24 to 1 as compared to a current ratio of 2.68 to 1 on March 31, 2005.

Mr. Liu continued, "In addition to remarkable organic growth dynamics in our existing products and markets, there continues to be a tremendous opportunity to make strategic and accretive acquisitions in China. While there are other companies that may also have an interest in pursuing these acquisitions, AOB has a unique ability to identify, access and complete the due diligence on these deals and more importantly, possesses the necessary expertise to leverage these opportunities and to successfully integrate the operations of these businesses into AOB. We remain focused on identifying acquisitions that will either enhance our presence in the PBP or PBN marketplace or broaden our distribution network for existing products. The recently completed acquisition of GLP has positioned AOB to accomplish both objectives. The product portfolio we acquired from GLP is complementary to our existing offering in the area of women's health and we believe we can significantly grow GLP revenues by improving the execution of sales and marketing programs and introducing AOB methodologies, which were so successful in the HSPL acquisition. The acquisition of GLP is also important for AOB as it further expands our geographic reach to southern part of China."

Mr. Liu concluded, "We continue to believe that we can meaningfully grow our revenues organically and through acquisitions. We are very well-positioned to execute on this strategy with a talented and experienced management team, a broad and deep existing product portfolio and a healthy balance sheet. We look forward with great anticipation to continued success in 2006."



Conference Call Information:



The Company will hold a conference call at 10 a.m. ET to discuss first quarter 2006 results. Interested participants should call 888-968-4564 when calling within the United States or 973-582-2841 when calling internationally. There will be a playback available until May 19, 2006. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 7360542 for the replay.

This call is being webcast by ViaVid Broadcasting and can be accessed at American Oriental Bioengineering's Web site at http://www.bioaobo.com. The webcast may also be accessed at ViaVid's Web site at www.viavid.net. The webcast can be accessed until June 12, 2006, on either site.



About American Oriental Bioengineering, Inc.



American Oriental Bioengineering, Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.



AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS
------ MARCH 31, DECEMBER 31,
2006 2005
------------ --------------
UNAUDITED
CURRENT ASSETS
Cash and cash equivalents $ 80,915,067 $ 57,532,049
Accounts receivable, net 9,494,257 8,168,420
Inventories, net 8,086,037 4,916,500
Advances to suppliers 1,264,680 3,494,320
Other receivables 5,285,138 102,611
Due from employees 661,947 409,159
Deferred consulting expenses 649,562 752,620
------------ --------------
Total Current Assets 106,356,688 75,375,679PLANT AND EQUIPMENT, NET 13,860,189 13,386,439
LAND USE RIGHTS, NET 7,935,607 7,925,763
CONSTRUCTION IN PROGRESS 1,331,196 1,655,349
DEFERRED TAX ASSETS 611,716 614,336
LICENSE, NET 444,368 464,673
------------ --------------
TOTAL ASSETS $130,539,764 $ 99,422,239
------------ ============ ==============
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------CURRENT LIABILITIES
Accounts payable $ 1,345,357 $ 1,230,767
Other payables and accrued expenses 1,980,818 1,604,096
Taxes payable 1,520,216 1,485,872
Short-term bank loans 3,742,048 3,717,380
Customer deposits 354,141 355,975
Other liabilities 517,303 168,080
------------ --------------
Total current liabilities 9,459,883 8,562,170DEFERRED TAX LIABILITIES 259,518 232,505
OTHER LIABILITIES 20,285 23,018
------------ --------------
TOTAL LIABILITIES 9,739,686 8,817,693
------------ --------------SHAREHOLDERS' EQUITY
Preferred stock, $0.001 par value;
2,000,000 shares authorized; 1,000,000
shares issued and outstanding at March
31, 2006 and December 31, 2005,
respectively 1,000 1,000
Common stock, $0.001 par value;
150,000,000 shares authorized;
62,635,788 and 57,109,188 shares issued
and outstanding, respectively 62,636 57,109
Additional paid-in capital 84,505,239 59,491,393
Retained earnings (the restricted
portion of retained earnings is
$4,104,115 and $4,104,115 at March 31,
2006 and December 31, 2005,
respectively) 34,542,299 29,625,765
Accumulated other comprehensive income 1,688,904 1,429,279
------------ --------------
Total Shareholders' Equity 120,800,078 90,604,546
------------ --------------
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY $130,539,764 $ 99,422,239
----------------------------------- ============ ============== AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
THREE MONTHS ENDED
MARCH 31,
2006 2005
----------- -----------
UNAUDITEDREVENUES $19,086,901 $ 9,652,782COST OF GOODS SOLD (6,509,411) (3,627,564)
----------- -----------GROSS PROFIT 12,577,490 6,025,218Selling and marketing expenses (1,701,280) (655,375)Advertising (2,225,187) (814,733)General and administrative expenses (1,880,964) (1,225,393)Depreciation and amortization (386,947) (304,982)
----------- -----------INCOME FROM OPERATIONS 6,383,112 3,024,735INTEREST INCOME (EXPENSE), NET 81,661 (91,675)OTHER EXPENSE, NET (988) - ----------- -----------
INCOME BEFORE INCOME TAXES 6,463,785 2,933,060INCOME TAXES (1,547,251) (749,871)
----------- -----------NET INCOME $ 4,916,534 $ 2,183,189
=========== ===========OTHER COMPREHENSIVE INCOME
Foreign currency translation gain 259,625 -
----------- -----------
Other comprehensive income before tax 259,625 -Income tax expense related to other
comprehensive income (85,676) -
----------- -----------
TOTAL OTHER COMPREHENSIVE INCOME, NET OF TAX 1,131,566 - ----------- -----------
COMPREHENSIVE INCOME 5,090,483 2,183,189
----------- -----------
NET INCOME PER SHARE
BASIC $ 0.08 $ 0.05
DILUTED $ 0.08 $ 0.05WEIGHTED AVERAGE NUMBER OF SHARES
OUTSTANDING
BASIC 61,223,435 39,746,827
DILUTED 61,318,674 42,701,898

[trueffelschweinchen]

In den letzten Monaten war es hier sehr ruhig um AOB.
Die Geschäftsentwicklung scheint weiterhin vielversprechend zu laufen, es gibt auch eine neue Aquisition:


American Oriental Bioengineering, Inc. (AMEX: AOB):

-- Marketing Initiatives in Place to Improve Sales



-- Synergies Identified to Expand GLP Margins



-- AOB Engages Ms. Ni Ping as Company Spokesperson



-- Acquisition Expected to Positively Contribute to 2Q06 and Full Year 2006; Revenues, Net Income and EPS



American Oriental Bioengineering, Inc. (AMEX: AOB), a leading manufacturer and distributor of pharmaceutical and nutraceutical products in China, provides update on the acquisition of Guangxi Lingfeng Pharmaceutical Company Limited (GLP). GLP is a manufacturer of plant-based pharmaceutical products in China, specializing in pediatrics, gynecopathy and medicines for the treatment of digestive and respiratory system illnesses.

"We are pleased to report that the integration of GLP has been progressing according to plan and we believe we have identified several areas where we can improve sales and reduce expenses to drive higher overall efficiency," commented Tony Liu, Chairman and Chief Executive Officer. "Similar to our acquisition of HSPL in September of 2004, where we improved sales by more than 300 percent and gross margins by nearly 20 percent in just over 12 months from the closing, we intend to create incremental value from our acquisition of GLP."

The acquisition of GLP has significantly expanded the plant based product (PBP) portfolio of AOB, contributing 70 potential products to the Company's existing PBP product offering. The acquisition of GLP has also increased AOB's points of distribution, particularly in Southern China, which has enabled the Company to better leverage its entire portfolio of PBP and plant based nutraceutical (PBN) products. GLP's flagship products, known as the Jinji Series, treat gynecological inflammations, such as endometritis and annexitis and are complementary to AOB's Cease Enuresis products for the treatment of bedwetting and nighttime urination.

In an effort to take advantage of its robust product portfolio, AOB has retained Ms. Ni Ping as the Company's official spokesperson. Ms. Ni Ping is a well known actor and television host within China, for her role in "Variety Wonderland", a primetime weekend special airing since 1990 and as the host of "Spring Festival Evening Party" which is estimated to have attracted more than one billion cumulative viewers during her tenure. With a now dedicated marketing budget, available resources and AOB's operational expertise, management's strategy is to improve GLP sales and profits from current levels.

"During the second quarter we will recognize over two months of contribution from GLP and expect the business to positively impact our reported results," Mr. Liu added. "Furthermore, I look forward to updating investors on our progress during our second quarter earnings conference call in August."



About American Oriental Bioengineering, Inc.



American Oriental Bioengineering, Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.



This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

[trueffelschweinchen]

Hier die aktuellen Zahlen fürs 2. Quartal 2006:
Umsatz- und Gewinnwachstum ist weiter voll intakt.


American Oriental Bioengineering Inc. (AMEX: AOB):



Second Quarter 2006 Highlights



-- Organic Revenue growth of 66% during the quarter



-- Acquisition of GLP was accretive to both revenues and net income during the second quarter and AOB anticipates an acceleration of growth and profitability in subsequent quarters from the subsidiary



-- GLP's gross margins and operating margins increase by approximately 7% and 13% respectively in less than three months since acquisition



-- Company announces the acquisition of HQPL subsequent to the close of the second quarter



American Oriental Bioengineering Inc. (AMEX: AOB), a leading Chinese manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the second quarter ended June 30, 2006.



Key Financial Indicators
(All numbers in thousands, except per-share amounts in USD) Q2 2006 Q2 2005 Percentage ChangeRevenues $22,762 $11,902 91.2%
Cost of goods sold $7,678 $4,189 83.3%
Gross Profit $15,083 $7,714 95.5%
Total Operating Expenses $8,078 $3,248 148.7%
Income from operations $7,006 $4,466 56.9%
Net Income $5,827 $3,356 73.7%
EPS -- Fully Diluted $0.09 $0.08 12.5%
Diluted Shares 62.8M 42.5M 47.7%




The U.S. dollar amounts are calculated based on the average conversion rate of US$1 to RMB 8.0 for the second quarter of 2006 and US $1 to RMB 8.3 for the second quarter of 2005.



Second Quarter 2006 Results



For the second quarter 2006, the company reported revenues of $22.8 million, an increase of 91.2 percent compared to $11.9 million in the second quarter of last year and up 19.3 percent compared to $19.1 million reported in the first quarter of 2006. Total revenues for the quarter increased both sequentially and year-over-year driven by strong organic growth in the company's Plant-based Pharmaceutical (PBP) and Plant-based Nutraceutical (PBN) line of products and as a result of the recent acquisition of Guangxi Lingfeng Pharmaceutical Co. Ltd. (GLP) during the quarter. During the second quarter, PBP sales, including GLP products, increased by 113.5 percent to $15.8 million compared to the second quarter last year. Revenues within this segment continue to benefit from strong sales of the company's Cease Enuresis and Shuanghuanlian Injection Powder products, which increased 138.8 percent and 46.7 percent respectively from the year ago period. GLP revenues during the second quarter totaled $3.0 million, which included just over two months of contribution during the quarter. Sales of PBN products in the second quarter of 2006 totaled $6.9 million, representing a 54.3 percent increase from the $4.5 million reported during the comparable period last year as we believe that our marketing efforts led to further penetration and greater brand awareness within the marketplace. An increase of 84.2 percent in sales of Protein Peptide series to $5.9 million had the biggest impact on PBN revenues during the second quarter 2006 as compared to the second quarter 2005.

"We are very pleased with both our revenue performance during the second quarter from an organic standpoint and the initial contribution from our acquisition of GLP," commented Tony Liu, chairman and CEO of AOB. "Our products continue to be well received by consumers looking to address specific ailments or to improve their overall health and well-being through traditional Chinese herbal remedies. We believe that the acquisition of HQPL announced last month will be accretive to future growth as it provides us with a significantly expanded distribution network encompassing all major regions within China."

Cost of goods sold were $7.7 million during the second quarter, representing an increase of 83.3 percent, compared to $4.2 million in the same period last year. Gross margins for the period were 66.3 percent compared to 64.8 percent in the second quarter of 2005 and 65.9 percent in the first quarter of 2006. Gross margins increased both sequentially and year over year due to improved operating efficiencies across both PBP and PBN businesses.

Total operating expenses for the second quarter were $8.1 million which represented an increase of 148.8 percent versus last year as the company increased expenses to support operational growth while also incurring additional expenses related to the GLP acquisition and integration. Selling and marketing expenses increased 255.5 percent to $2.0 million primarily related to the increased spending on promotional materials and higher marketing fees. Compared to the second quarter of last year advertising expenses increased 409.4 percent to $3.0 million, and general and administrative expenses increased 35.1 percent to $2.4 million. Operating income increased to $7.0 million, up 56.9 percent compared to $4.5 million in the year ago period. Operating margins were 30.8 percent as compared to 37.5 percent last year and 33.4 percent in the first quarter 2006.

The company had an effective tax rate of 21.0 percent compared to 23.6 percent last year. This tax is in addition to the Value Added Tax (VAT) of 17.0 percent deducted from the company's gross revenues each quarter. Net income increased 73.7 percent to $5.8 million or $0.09 per fully diluted share versus net income of $3.4 million or $0.08 per fully diluted share in the same period last year. Fully diluted earnings per share increased 12.5 percent year over year.

For the sixth month period ending June 30, 2006, revenues increased 93.7 percent to $41.8 million as compared to $21.6 million last year. Organic revenue growth for the period was 80.0 percent. Gross profit increased 101.1 percent to $27.6 million resulting in a gross margin of 66.1 percent as compared to 63.7 percent in the comparable period last year with operational efficiencies previously highlighted. Operating income increased 78.5 percent to $13.4 million with resulting operating margins of 32.0 percent versus 34.8 percent last year with the resulting year over year decrease as a result of higher overall expenses. Net income for the period totaled $10.7 million as compared to $5.5 million last year representing a 93.8 percent increase. Fully diluted earnings per share increased 30.8 percent to $0.17 for the six month period ending June 30, 2006, as compared to $0.13 last year despite the 46.2 percent increase in weighted average fully diluted shares outstanding to 62.1 million and 42.5 million respectively.

The company completed the quarter with $70.3 million in cash and cash equivalents. Cash and cash equivalents increased $12.8 million from $57.5 million at the end of 2005 primarily as a result of $8.6 million in positive cash flow from operations through the first six months of 2006, $25.0 million in the receipt of cash proceeds from the second tranche of the private placement effected in December 2005, offset by the net cash purchase price of GLP for $18.1 million. Free cash flow for the sixth-month period ending June 2006 was $7.9 million. Inventory at the end of the second quarter totaled $10.4 million, representing a 111.0 percent and 28.3 percent increase respectively as compared to the end of second quarter 2005 and the end of fourth quarter 2005. Management believes inventory is at acceptable levels given the revenue growth experienced during the first six months of 2006 versus last year and future growth plans. The company continues to have quality receivables with overall Days Sales Outstanding (DSO) decreasing 11 days from both the end of 2005 and the first quarter 2006 to 34 days.

Regarding the ongoing opportunity to derive value from the recent GLP acquisition, Liu commented, "Similar to our experience with the acquisition of HSPL, and based on initial GLP results, we have identified significant operational synergies which we expect will translate into improved margins for both GLP and AOB on a combined basis. Our expectation is that GLP margins can be comparable to that of AOB by the end of 2006."

Liu concluded, "We have continued to make significant operational and organizational improvements to AOB during the past year. By significantly expanding both our product portfolio and distribution channels we believe that we have built a solid foundation to leverage these assets into incremental future revenue, margin and net income growth opportunities."



Conference Call Information



The company will hold a conference call at 4:45 p.m. ET to discuss second quarter 2006 results. Interested participants should call 877-692-2591 when calling within the United States or 973-582-2845 when calling internationally. There will be a playback available until Aug. 21, 2006. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use pass code 7673291 for the replay.

This call is being webcast by ViaVid Broadcasting and can be accessed at American Oriental Bioengineering's Web site at http://www.bioaobo.com. The webcast may also be accessed at ViaVid's Web site at www.viavid.net. The webcast can be accessed until Sept. 14, 2006, on either site.

[Bachalor]

Antwort auf Beitrag Nr.: 23.478.107 von trueffelschweinchen am 17.08.06 10:14:05

ich finde die zahlen für ein recht junges unternehmen recht gut

konstantes wachstum über längere zeit bringt sicherheit in den stock

[Bachalor]

zur zeit nur grüne tage

[berndh70]

NEW YORK--(BUSINESS WIRE)--

American Oriental Bioengineering, Inc. (AMEX: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced GLP has received over $6.0 million in orders for its Jinji Series of products which are expected to be delivered during the fourth quarter.

By leveraging AOB's marketing methodologies, its expanded distribution points and new advertising and marketing campaigns, AOB has begun to see an accelerating pace of business for GLP products. Specifically, the Company hired Ms. Ni Ping, a well known and recognized Chinese celebrity to endorse the Jinji Series of products which targets women's health. Additionally, AOB has implemented a comprehensive training program geared to further educating GLP salespeople and improving the overall level of sales execution. GLP's position in the market is strengthening as the products now have nationwide access to China through AOB's 100,000 distribution points.

"We are very pleased to see a further increase in revenue from our integration of GLP since April," commented Mr. Tony Liu, Chairman and Chief Executive Officer of AOB. "This level of order activity prior to the start of a quarter represents a record for GLP and we are comfortable with our manufacturing capacity to address further anticipated revenue growth. Strong demand for the products has necessitated AOB to manufacture during the China National Day Holiday, a time when many facilities are closed. We remain committed to establishing the Jinji Series as a top three brand in women's health in China and having the brand contribute significantly to AOB's total revenue."

[Bachalor]

die 6$ sind hartnäckig

[Bachalor]

Antwort auf Beitrag Nr.: 24.390.804 von Bachalor am 04.10.06 01:16:17

6 überschritten


ob sie halten

[trueffelschweinchen]

Der Widerstand ist geknackt:

heute abend +7% an der AMEX und auf Tageshoch geschlossen...

[Bachalor]

Antwort auf Beitrag Nr.: 24.527.532 von trueffelschweinchen am 09.10.06 22:54:53

war mir fast zu viel heute


wenn der umsatz und gewinn weiterhin konstant steigt
wird es hier noch richtig

[berndh70]

Antwort auf Beitrag Nr.: 24.528.124 von Bachalor am 10.10.06 00:18:18

@ Bachalor

das sehe ich auch so. Aber die 6$ scheinen jetzt doch zu halten. Sicher geht es da kurzfristig wieder nach unten, aber das 4 Quartal ist auch hier bisher immer das stärkste gewesen. Deshalb bin ich für das Jahresende sehr positiv gestimmt. Und Du sagst ja, wenn Umsatz und Gewinn weiter so laufen, dann müssen wir uns wenig Sorgen machen...

[Bachalor]

war nicht zuviel


sieht gut aus mit 7$

[Bachalor]

die letzten 2 tage durchkonsolitiert


und heute ist die sex $ marke geschichte

[berndh70]

Antwort auf Beitrag Nr.: 17.734.358 von ProMaiLer am 30.08.05 23:42:10

Na, das sieht doch mal wieder nach guten Nachrichten aus...

III. Quartal Umsatz +102% vgl. zu III/2005
Ergebnis pro Aktie voraussichtlich +38%

NEW YORK--(BUSINESS WIRE)--


....

The Company expects to report revenue of approximately $27 million for the third quarter 2006, which would represent a 102 percent increase from the third quarter of last year based on continued strength across all major product lines. AOB expects to report earnings per share of at least $0.11 for the third quarter 2006, which would represent 38 percent increase from last year.

....

[Bachalor]

Antwort auf Beitrag Nr.: 24.800.990 von berndh70 am 23.10.06 16:00:39

jetzt sollten die 7 in angriff genommen werden

[Bachalor]

[Bachalor]

Antwort auf Beitrag Nr.: 24.801.501 von Bachalor am 23.10.06 16:19:25

heute fallen die7$

[Bachalor]

Antwort auf Beitrag Nr.: 24.529.108 von berndh70 am 10.10.06 08:57:33

es läuft konstant weiter





und das beste quartal kommt noch

[Bachalor]

die 7 sind wohl vergangenheit

[berndh70]

na, das geht ja heute richtig gut los!
normalerweise war das in letzten Jahr immer anders. Wenn gute Zahlen rauskamen, dann ist die Aktie gefallen. Ich denke die kurzfristigen Trader haben dann ihre Positionen im Fahrwasser der guten News abgegeben. Das war am Tag als jetzt die Zahlen rauskamen ebenfalls so. Aber so kurz danach solche Kurse, das stimmt doch zuversichtlich...

[Bachalor]

wenn das th nochmal fällt
gibt es noch einen schub

rechne mit sk um 7.60

[trueffelschweinchen]

Hab ich gerade zufällig gefunden:



American Oriental Bioengeneering "buy"

31.10.2006
Brean Murray, Carret & Co

Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Brean Murray, Carret & Co stufen die Aktie von American Oriental Bioengeneering (ISIN US0287311072 / WKN 590111) in ihrer Ersteinschätzung mit "buy" ein. Das Kursziel liege bei 9,00 USD. (31.10.2006/ac/a/u)

[Bachalor]

heute fallen noch die 8

[Bachalor]

Antwort auf Beitrag Nr.: 25.218.116 von Bachalor am 08.11.06 16:06:02

das waren die 8

[Bachalor]

Antwort auf Beitrag Nr.: 25.093.138 von trueffelschweinchen am 02.11.06 23:16:30

die können kursziel erhöhen

[trueffelschweinchen]

Stimmt, die Aktie läuft in einem schönen Aufwärtstrend.
Charttechnisch sieht auch alles bestens aus.
Zur Zeit einfach zurücklehnen und laufen lassen, bis zum Jahresende kommen bestimmt noch ein paar Prozente zusammen

[Bachalor]

Antwort auf Beitrag Nr.: 25.230.114 von trueffelschweinchen am 08.11.06 22:31:31

747137

denke ich wird auf 4.5-5€ laufen
heute waren gewinnmitnahmen

[Bachalor]

Antwort auf Beitrag Nr.: 25.230.341 von Bachalor am 08.11.06 22:38:15

sollte bm geben

[trueffelschweinchen]

Antwort auf Beitrag Nr.: 25.230.352 von Bachalor am 08.11.06 22:38:39

Verstehe Deine letzten beiden Beiträge nicht ganz...

[berndh70]

Gestern nachbörslich in Amerika bis auf 9,98$ - Grund:

American Oriental Bioengineering Inc. Reports Record Quarterly Revenue and Earnings and Provides Guidance for Fourth Quarter 2006
Revenues Increase 101.9% Versus Last Year; Net Income Increases 103.5%; EPS increases 50% to $0.12

Hier der Rest des Artikels:

http://www.nasdaq.com/aspxcontent/NewsStory.aspx?cpath=20061…

[Bachalor]

Antwort auf Beitrag Nr.: 25.411.564 von berndh70 am 15.11.06 15:06:56

[[KERN]Codex]

Antwort auf Beitrag Nr.: 25.411.933 von Bachalor am 15.11.06 15:20:21

[Bachalor]

Antwort auf Beitrag Nr.: 25.412.052 von [KERN]Codex am 15.11.06 15:24:14

das bräuchte endlich mal biph
konstante ein-und gewinnsteigerungen
dann geht es dort richtig ab

nurob und wann

[Barde69]

Antwort auf Beitrag Nr.: 25.412.080 von Bachalor am 15.11.06 15:25:22

zeit für eine korrektur - sell on good news - bei 10! aktie wird wieder auf ca. 8,50 zurück um dann neu zu starten.

[berndh70]

das wir die 10$ noch in diesem Jahr sehen werden hätte ich nicht gedacht. WoW!

[Bachalor]

sind hier alle geschockt vom verlauf

[Bachalor]

die aktie ist der hit
2-3 tage konsi und weiter geht es

[trueffelschweinchen]

Heute bei $12,10 geschlossen, +12%.
Wenn das so weitergeht, sehen wir dieses Jahr noch die 10 Euro.

[trueffelschweinchen]

Das dürfte ein Grund für die große Nachfrage der letzten Tage sein:

American Oriental Bioengineering Announces Approval for Listing on New York Stock Exchange

NEW YORK, Nov. 28 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, (Nachrichten) Inc., (Amex: AOB; NYSE Arca: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, announced today it has received approval for listing on the New York Stock Exchange (NYSE). The Company anticipates its shares of common stock will begin trading on the NYSE on December 18, 2006. Until that time, the Company's shares will continue to trade on the American Stock Exchange and the NYSE Arca exchange under the symbol "AOB".

"We are proud to be among a very select group of China-based companies to list on the NYSE, as well as the first China-based pharmaceutical and nutraceutical company to list on the NYSE, and we expect this event to raise our visibility in the global financial markets. By transferring to one consolidated trading platform at the NYSE, we believe we can achieve greater price efficiency which will ultimately more accurately reflect shareholder value," said Tony Liu, Chairman and CEO of AOB. "We thank our partners at the American Stock Exchange and the NYSE Arca for the important role they played in our evolution. We are excited to move forward with this new chapter in our Company's history."

AOB's products are distributed throughout all 28 provinces in China. The market for pharmaceutical products in China is expected to be the world's largest by 2020, and is currently estimated at $50 billion. The Company listed on the American Stock Exchange in July 2005 and on the NYSE Arca in November 2005. Today, AOB has a market capitalization of over $600 million and net cash per share of $0.97 as of September 30, 2006. AOB reported third quarter 2006 revenue growth of 102% to $27.0 million and net income growth of 104% to $7.6 million versus the prior year's quarter.

"AOB provides many of the leading pharmaceutical and nutraceutical products in China, and is a known brand in one of the world's largest healthcare markets," said John A. Thain, CEO of NYSE Group, Inc. "On behalf of the NYSE Group, I am very pleased to extend our relationship with AOB as the company enters the next stage of growth and look forward to providing the highest levels of market quality to the company and its shareholders."

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com/.

About NYSE Group, Inc.

NYSE Group, Inc. operates two securities exchanges: the New York Stock Exchange (the "NYSE") and NYSE Arca, Inc. (formerly known as the Archipelago Exchange, or ArcaEx(R), and the Pacific Exchange). NYSE Group is a leading provider of securities listing, trading and market data products and services. In the third quarter of 2006, on an average trading day, 2.2 billion shares, valued at $80.1 billion, were traded on the exchanges of the NYSE Group.

The NYSE is the world's largest and most liquid cash equities exchange. The NYSE provides a reliable, orderly, liquid and efficient marketplace where investors buy and sell listed companies' common stock and other securities. On September 30, 2006, the operating companies listed on the NYSE represented a total global market capitalization of $23.1 trillion.

NYSE Arca operates NYSE Arca, Inc., the first open, all-electronic stock exchange in the United States, and has a leading position in trading exchange-traded funds and exchange-listed securities. NYSE Arca, Inc. is also an exchange for trading equity options. NYSE Arca's trading platforms provide customers with fast electronic execution and open, direct and anonymous market access.

NYSE Regulation, an independent not-for-profit subsidiary, regulates member organizations through the enforcement of marketplace rules and federal securities laws. NYSE Regulation also ensures that companies listed on the NYSE and NYSE Arca meet their financial and corporate governance listing standards.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

[Bachalor]

Antwort auf Beitrag Nr.: 25.966.161 von trueffelschweinchen am 06.12.06 10:15:21

langsam wäre mal zeit für eine solide konsi

























oder auch nicht

[berndh70]

Antwort auf Beitrag Nr.: 17.734.358 von ProMaiLer am 30.08.05 23:42:10

Heute fährt die Aktie wohl die erwartete Korrektur ein. Aktuell schon -1$ oder -7,8%

[Bachalor]

Antwort auf Beitrag Nr.: 26.180.802 von berndh70 am 14.12.06 17:45:10

alles halb so wild

[berndh70]

Antwort auf Beitrag Nr.: 26.180.841 von Bachalor am 14.12.06 17:46:32

@bachalor: gemessen an dem Anstieg der letzten Zeit stimmt das. Und an den fundamentalen Daten der Aktie ändert sich nichts. Ab Montag gehts dann an der NYSE weiter. Bin schon sehr gespannt.

[Bachalor]

Antwort auf Beitrag Nr.: 26.180.962 von berndh70 am 14.12.06 17:51:11

ich denke
es wird erstmal richtung 9-10$ laufen

die NYSE ist dicke eingepreist
der anstieg die letzten 18 monate war zu viel

nur m.m

muss nicht stimmen

[berndh70]

Antwort auf Beitrag Nr.: 26.181.010 von Bachalor am 14.12.06 17:53:34

Langfristig wird das Uplisting helfen. Wenn der Umsatz und die Ergebnisse der Firma weiter so laufen, dann brauchen wir uns wenig Sorgen machen. Die haben ja sozusagen gerade erst angefangen...

[Bachalor]

Antwort auf Beitrag Nr.: 26.181.125 von berndh70 am 14.12.06 17:58:22

die mk beträt bereits 800.000.000$


in meinen augen etwas viel für umsatz und gewinn zur zeit


wenn es so weiterläuft ist das sicherlich recht was du schreibst

[berndh70]

Antwort auf Beitrag Nr.: 26.181.200 von Bachalor am 14.12.06 18:00:42

Das eine Konsolidierung kommen mußte war klar. Und ich bin voll auf Deiner Seite. Hohe Marktkapitalisierung und zu starker Anstieg in der letzten Zeit.

Meine Entscheidung für die Aktie ist nach wie vor langfristig:
Die Firma stellt medizinische Produkte auf planzlicher Basis her. Bisher werden die Produkte hauptsächlich in China vertrieben. Die Chinesen sind traditionell eher diesen Produkten zugetan als der westlichen Medizin. Und bei uns geht der Trend auch immer mehr in diese Richtung.

Dazu kommt das Nahrungs-Ersatzmittel für Milcheiweiß, für das viele Asiaten eine Unverträglichkeit haben. Ich denke, da wird bald die erste Exportentscheidung für den Vertrieb in andere Länder fallen. Mit Eileen Brody haben sie sich ja schon jemanden für diesen Schritt ins Boot geholt.

Wie siehst Du die langfristige Entwicklung?

[Bachalor]

langfristig sicher positiv
ich denke halt,dass es erstmal eine kräftige konsi gibt

die aufnahme in nyse war ja wie ein ritterschlag auf lange sicht



du hast bm

[Bachalor]

Antwort auf Beitrag Nr.: 26.181.642 von berndh70 am 14.12.06 18:16:18

die nyse
war wohl wirklich schon dicke drin





rechne noch mit kursen bis 9.20-9.50$

[trueffelschweinchen]

Bin zum Glück noch zu 9,60 und 9,20 Euro ausgestiegen.
Die Aktie war mir wie Du auch schon geschrieben hast etwas zu heiss gelaufen.
Hätte aber auch nicht gedacht, dass es gleich am ersten NYSE Tag so abwärts geht.
Viel Glück allen verbliebenen AOB Aktionären.

[Bachalor]

Antwort auf Beitrag Nr.: 26.287.579 von trueffelschweinchen am 18.12.06 22:25:23

haben wir scheinbar zu früh geworfen




naja,bei kk von unter 2$

[DeltaComet]

na da waren ja einige recht früh dran. herzlichen glückwunsch an alle investierten, die die nerven hatten die aktie seit über einem jahr durchzuhalten.
bin auf aob leider erst seit kurzem aufmerksam geworden.
klar ist natürlich, das die mk sehr hoch ist. das ist aber meistens so bei wachstumsaktien mit umsatzanstiegen von über 100%, rekordgewinnen und rekordumsätze.

man sollte einfach so nach dem motto denken: "qualität hat seinen preis"

falls nächste woche das ath fällt bin ich mit
stop-buy dabei.

oh, das reimt sich ja, und was sich reimt ist gut.

zitat: pumukl

[Bachalor]

Antwort auf Beitrag Nr.: 26.592.699 von DeltaComet am 31.12.06 00:59:19

hoffe deine ek war aber noch unter 10$

[DeltaComet]

Antwort auf Beitrag Nr.: 26.598.142 von Bachalor am 31.12.06 08:46:16

hoffe deine ek war aber noch unter 10$

wieso? ich bin doch noch garnicht dabei.
ich werde einsteigen, wenn aob nächste woche das ath knacken sollte!!

[Robse6969]

Wirtschaftsnews - von heute 19:02

China-Titel drehen an der US-Börse "frei"

New York 03.01.07 (emfis.com)
Etliche chinesische Unternehmen, welche auch an der US-Börse gehandelt werden, gehören dort heute zu den Top Gewinnern.
So geht die Shanghaier Semiconductor Manufacturing Int. um satte 22 Prozent auf 7,85 US Dollar nach oben. Dem steht die China Life Insurance Co. nicht viel nach. Sie katapultiert sich um 14 Prozent auf 57,48 US Dollar hoch. Mit einem Prozentsatzvon 7,2 geht es mit der Greater China Fund Inc. auf 33,75 US Dollar nach oben.
Die Mindray Medical International Ltd. kann sich um 7,7 Prozent auf 25,75 US Dollar verbessern. Die American Oriental Bioengineering Inc. schafft immerhin noch einen Zugewinn von 6 Prozent auf 13,37 US Dollar.
Das Hongkonger Schwergewicht China Mobile Ltd. beeindruckt mit einem Plus von 7,8 Prozent auf 46,59 US Dollar und die Sinopec Shanghai Petrochemical Co. ist mit einem Plus von 5,6 Prozent auf 52,30 US Dollar dabei.
Da noch gehandelt wird, können die genannten Kurse schwanken.





Quelle: EMFIS.COM, Autor: (il)

[Raggamuffin]

so ruhig hier

[trueffelschweinchen]

Antwort auf Beitrag Nr.: 27.350.141 von Raggamuffin am 01.02.07 16:39:26

vorbei ist's mit der Ruhe.

Hat jemand ne erklärung für den heftigen 25% Absturz?

Die folgende Meldung allein kanns eigentlich nicht gewesen sein.
Na ja, ich war mal mutig und habe entgegen den Regeln ins fallende Messer gegriffen.

Hier die Meldung:
NEW YORK, March 12 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, (Nachrichten) Inc. , a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2006.

Revenue for the fourth quarter of 2006 increased 108.7% to $41.3 million from $19.8 million in the fourth quarter of 2005. Revenue growth reflects continued demand for the Company's leading PBP and PBN products, as well as a $12.7 million contribution from the GLP acquisition. Revenue from PBP products increased 159.2% to $31.5 million from $12.1 million in the prior year's fourth quarter, driven by increased demand for Shuanghuanglian Injection Powder, Cease Enuresis Soft Gel and UrinStopper Patch. Revenue from PBN products increased 28.4% to $9.8 million from $7.6 million from the fourth quarter of 2005, due to increased demand for the Company's Protein Peptide products.

Gross profit in the fourth quarter of 2006 increased 116.0% to $27.2 million from $12.6 million in the fourth quarter of 2005. Gross margin increased 220 basis points to 65.9% from 63.7% in the prior year's period. The increase in gross profit was a result of higher sales, improved gross margins and operating efficiencies across PBP and PBN businesses.

Operating expenses in the fourth quarter increased 112.6% to $13.6 million compared to $6.4 million in the prior year period. This increase was primarily due to increased marketing materials, payroll and shipping expenses commensurate with sales growth. Additionally, the Company continued to increase advertising expenditure as it invests in brand strength, particularly related to products acquired with the GLP business. Operating income for the fourth quarter increased 119.6% to $13.6 million from $6.2 million in the fourth quarter of 2005. Operating margin as a percent of sales in the fourth quarter increased 170 basis points to 33.1% compared to 31.4% in the prior year period.

Net Income for the fourth quarter of 2006 increased 161.1% to $10.9 million, or $0.17 per diluted share, compared to $4.2 million, or $0.10 per diluted share, in the prior year's period.

Fiscal 2006 Financial Results

Revenue for fiscal 2006 surpassed $100 million in sales, increasing 101.3% to $110.2 million from $54.7 million in 2005. Net Income for 2006 increased 117.5% to $29.2 million, or $0.46 per diluted share, compared to $13.4 million, or $0.31 per diluted share, in the prior year.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering commented, "We are pleased to report another strong quarterly and fiscal year performance. Revenue exceeded $41 million in the fourth quarter and exceeded $110 million for the year reflecting continued strong growth in both PBP and PBN product categories. In 2006 we focused on a number of core strategic initiatives including improving the breadth and quality of our product portfolio, penetrating new markets and rationalizing our administrative, manufacturing and distribution cost structures. We achieved success in these areas through accretive acquisitions and through a program of continuous internal efficiency improvements."

Fiscal 2007 Financial Update

For the first quarter of fiscal 2007, the company anticipates revenue to be in the range of $24 to $25 million and anticipates diluted earnings per share of approximately $0.10. This is based on a diluted share count of approximately 66.5 million shares outstanding.

For the 2007 fiscal year, the Company anticipates revenue to be in the range of $143-$147 million. This guidance does not account for any potential acquisitions in 2007.

Mr. Liu concluded, "Moving into 2007, we intend to continue to market our leading brands, develop new products and line extensions, further expand our channels of distribution, identify further cost savings throughout our business and pursue acquisitions that will be complimentary to our current business. We are committed to remaining a leader and innovator in the area of women's health and believe our initiatives in 2007 will continue to enhance our performance and expand our presence in the marketplace. We are energized with our opportunities and will continue to work aggressively to maximize return for our shareholders."

The Company will conduct a conference call to discuss the fourth quarter and 2006 full year results today, Monday, March 12, 2007 at 4:30 p.m. ET. Listeners may access the call by dialing #800-817-4887 or #913-981-4913 for international callers. A replay of the call will be available through March 19, 2007. Listeners may access the replay by dialing #800-203-1112 or #719- 457-0820 for international callers, passcode 1894285. A live webcast of the call will be broadcast at http://www.viavid.net/.

[Raggamuffin]

antwort ??

pahh

der ausblick ist bescheiden fürs nächste quartal aber für das gesamtjahr erwarten sie wieder 30% wachstum.

anscheinend wurde mehr erwartet

den conference call haben sie auch versaut da waren sehr viele unzufrieden mit

mich hats bissle bös erwischt hab nochmal nachgekauft vor den zahlen und dann sowas

hab aber nach dem sturz um 8,77 us$ nochmal zugegriffen. bin zwar noch im minus aber das haben wir bald erledigt.

100 mio cash bald da lässt sich ja was machen damit. (übernahme)
und die nächsten zahlen werden wieder überraschen und von der antwort der anleger auf den conference call werden sie auch gelernt haben. kann also nur besser werden.

tony liu (ceo) hat auch wieder zugegriffen 30.000 stück um 8,75

[Raggamuffin]

die 10.00 US$ sind essentiell

brechen wir da durch gehts weiter rauf einmal haben wirs schon versucht und sind gescheitert mal sehen was der heutige tag bringt

[Raggamuffin]

AOB wird international

American Oriental Bioengineering Expands International Exports to Canada
Wednesday March 28, 7:30 am ET
Canada Accepts AOBO's Jinji Pharmaceutical Products for Retail Distribution

NEW YORK, March 28 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB - News), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, announced today the signing of a new contract with a national exporter of pharmaceutical and nutraceutical products in China. Under the terms of the contract, the distributor will supply Jinji products to pharmacies in Canada. AOBO's Jinji exports are classified as over-the-counter (OTC) plant-based pharmaceuticals, meeting the rigorous safety and efficacy requirements in Canada.

Tony Liu, Chief Executive Officer of AOBO commented, "Today's announcement marks an important milestone for our Company as we capitalize on the exciting opportunities for our leading plant-based pharmaceutical products outside of China. Currently, most traditional Chinese medicine sold in Western markets is classified as food or dietary supplements rather than as medicinal products, which require a more stringent approval process. While today's announcement is not expected to have a material impact to the company's near-term financial results, the significance is incredibly meaningful for us. It marks the first time that AOBO's plant-based pharmaceutical products are classified as medicinal products in the Canadian market and this speaks to our consistent focus on quality and our ability to meet Western safety standards. Our Jinji products will be sold as medicine, alongside Western OTC drugs in the pharmacies. We expect our international export strategy will play an important role in the Company's long-term growth plan."

"We believe that the overall demand and acceptance of plant-based pharmaceutical products is increasing outside of China, and this presents a compelling new market for us. We expect to explore additional opportunities for penetration abroad in the future," added Liu.

[Raggamuffin]

hmm wann werden die shorties endlich gegrillt bei aob. heute vielleicht?

[Raggamuffin]

Zahlen am Montag und dann werden die shorties gegrillt nach den letzten zahlen wurde aob geprügelt weil der ausblick für 2007 so ausgegeben wurde wie erwartet mit 30% steigerung bei umsatz und gewinn. und am montag wird aob zeigen dass sie den ausblick übertreffen werden wie immer.

ist hier niemand mehr investiert??? es ist so ruhig hier. und das bei der story.

[trueffelschweinchen]

Für mich sind die Zahlen und vor allem die Perspektive absolut überzeugend.
Die Aktie wächst weiterhin kontinuierlich bei Umsatz und Gewinn und es ist auch überhaupt kein Ende absehbar.
Für mich eine Langzeitinvest mit ausgespochen gutem Chance/Risiko Verhältnis. Man muss der Aktie nur Zeit geben, dann wird man viel Freude haben.

Hier die Zahlen und der Ausblick für 2007:

07.05.2007 22:04
American Oriental Bioengineering Reports First Quarter 2007 Financial Results

NEW YORK, May 7 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, (Nachrichten) Inc. , a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, today announced financial results for the first quarter of 2007.

Revenues for the first quarter of 2007 increased 34.8% to $25.7 million from $19.1 million in the first quarter of 2006. This increase reflects $6.4 million in revenue from the Company's Jinji product portfolio, as well as year over year growth in the Company's core PBP and PBN products. Revenue from PBP products increased 52.4% to $18.6 million from $12.2 million in the prior year's first quarter, driven primarily by the Jinji products series, including the Company's newly launched Yi Mu Cao product for the relief of pre-menstrual symptoms, and by the Cease Enuresis Patch. Revenue from PBN products increased 3.7% to $7.2 million from $6.9 million from the first quarter of 2006, due to increased demand for the Company's soy peptide products.

Gross profit in the first quarter of 2007 increased 44.1% to $17.7 million from $12.3 million in the first quarter of 2006. Gross profit margin increased 440 basis points to a record 68.8% from 64.4% in the prior year's period. The increase in gross profit was a result of increased sales of PBP products, which carry higher margins and improved operating efficiencies across both business segments.

Operating expenses in the first quarter increased 65.8% to $9.8 million compared to $5.9 million in the prior year period. This increase was a result of additional expenses related to GLP that was not associated with the company in the prior year period, as well as increased marketing and advertising expenses related to the Company's efforts to increase market awareness of its brands and products. Operating income for the first quarter increased 24.0% to $7.9 million from $6.4 million in the first quarter of 2006. Operating profit as a percent of sales in the first quarter decreased 260 basis points to 30.8% compared to 33.4% in the prior year period.

Net Income for the first quarter of 2007 increased 31.1% to $6.4 million, or $0.10 per diluted share, compared to $4.9 million, or $0.08 per diluted share, in the prior year period.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering commented, "We are pleased to report another quarter of continued growth in our business. Our major plant-based pharmaceutical and nutraceutical categories contributed to our revenue growth in the first quarter with the biggest contribution coming from our over the counter (OTC) products. Our newly launched Jinji Yi Mu Cau product contributed to our results in the quarter and we are satisfied with the momentum of this product as we move into the second quarter. We continued to effectively manage our operating costs and sourcing efficiencies and were pleased to see stable pricing for our leading products, all of which resulted in record gross margin."

Fiscal 2007 Financial Update

For the second quarter of fiscal 2007, the Company anticipates revenue of approximately $33.0 million, a 45% increase compared to second quarter 2006 revenues of $22.8 million, with the majority of this revenue growth coming from products that serve the OTC market, primarily the Jinji product portfolio. The Company anticipates diluted earnings per share of approximately $0.14, based on a diluted share count of approximately 66.6 million shares outstanding.

For the 2007 fiscal year, the Company anticipates revenues to increase at least 32% from the prior year to at least $146.0 million. This guidance does not account for any potential acquisitions in 2007.

Mr. Liu concluded, "We continue to focus on opportunities that will further enhance the presence of our leading product brands and strengthen the total number of plant-based healthcare products in our portfolio. Consumer awareness of our brands continues to grow through our marketing efforts and the ongoing expansion of our diverse channels of distribution.

We also remain highly focused on the introduction of new products through the pursuit of complimentary acquisitions and additional product line extensions. We believe that these initiatives will better position our company for future growth and will further establish AOBO as a leading integrator and cultivator of plant-based traditional Chinese medicine products."

The Company will conduct a conference call to discuss the first quarter of 2007 results today, Monday, May 7, 2007 after the market close at 4:30pm ET. Listeners may access the call by dialing 1-888-802-2269 or 1-913-312-1272 for international callers. A webcast will also be available on AOB's website at http://www.bioaobo.com/. A replay of the call will be available through May 14, 2007. Listeners may access the replay by dialing 1-888-203-1112 or 1-719-457-0820 for international callers, password 8515435.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com/.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) THREE MONTHS ENDED MARCH 31, 2007 2006 REVENUES $25,722,577 $19,086,901 COST OF GOODS SOLD 8,018,260 6,797,715 GROSS PROFIT 17,704,317 12,289,186 Selling and marketing 2,702,351 1,701,280 Advertising 3,822,911 2,225,187 General and administrative 2,933,066 1,880,964 Depreciation and amortization 333,462 98,643 Total operating expenses 9,791,790 5,906,074 INCOME FROM OPERATIONS 7,912,527 6,383,112 INTEREST INCOME, NET 17,759 81,661 OTHER INCOME (EXPENSE), NET 39,084 (988) INCOME BEFORE INCOME TAXES 7,969,370 6,463,785 INCOME TAXES 1,523,103 1,547,251 NET INCOME 6,446,267 4,916,534 OTHER COMPREHENSIVE INCOME Foreign currency translation gain 1,210,147 259,625 Income tax expense related to other comprehensive income (399,349) (85,676) TOTAL OTHER COMPREHENSIVE INCOME, NET OF TAX 810,798 173,949 COMPREHENSIVE INCOME $7,257,065 $5,090,483 NET INCOME PER SHARE BASIC $0.10 $0.08 DILUTED $0.10 $0.08 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC 64,608,561 61,223,435 DILUTED 66,545,541 61,318,674 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS MARCH 31, DECEMBER 31, 2007 2006 UNAUDITED CURRENT ASSETS Cash and cash equivalents $93,442,093 $87,784,419 Accounts receivable, net of reserve of $54,878 and $39,776 at March 31, 2007 and December 31, 2006, respectively 10,469,500 11,141,057 Inventories, net of $596,360 and $615,552 provision for slow moving inventories at March 31, 2007 and December 31, 2006, respectively 13,224,691 10,684,316 Advances to suppliers 2,533,640 1,950,101 Notes receivable 1,812,275 3,238,161 Other receivables 32,323 37,545 Due from employees 351,984 585,050 Deferred consulting expenses 310,800 166,600 Total Current Assets 122,177,306 115,587,249 LONG-TERM ASSETS Plant and equipment, net 32,706,985 32,194,957 Land use rights, net 33,078,441 32,937,743 Construction in progress 314,545 326,121 Deferred tax assets 1,657,731 1,797,153 License, net 363,328 383,755 Goodwill 1,933,100 1,933,100 Long-term investment and advance 138,208 113,868 Total Long-Term Assets 70,192,338 69,686,697 TOTAL ASSETS $192,369,644 $185,273,946 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS LIABILITIES AND SHAREHOLDERS' EQUITY MARCH 31, DECEMBER 31, 2007 2006 UNAUDITED CURRENT LIABILITIES Accounts payable $2,945,328 $2,871,981 Other payables and accrued expenses 2,633,659 4,549,867 Taxes payable 1,177,561 2,211,542 Short-term bank loans 7,750,987 8,314,679 Current portion of long-term bank loans 1,453,565 1,450,905 Customer deposits 3,194,000 2,263,654 Notes payable 66,455 66,216 Other liabilities 864,075 1,606,334 Total Current Liabilities 20,085,630 23,335,178 LONG-TERM LIABILITIES Long-term bank loans, net of current portion 911,847 915,909 Long-term notes payable 262,435 255,836 Deferred tax liabilities 4,614,058 4,580,698 Other liabilities 5,399 9,083 Total Long-Term Liabilities 5,793,739 5,761,526 TOTAL LIABILITIES 25,879,369 29,096,704 SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at March 31, 2007 and December 31, 2006, respectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 64,784,359 and 64,230,369 shares issued and outstanding, respectively 64,784 64,230 Stock to be issued 297,500 599,069 Additional paid-in capital 95,265,594 92,307,960 Retained earnings (the restricted portion of retained earnings is $8,498,766 at March 31, 2007 and December 31, 2006, respectively) 65,273,178 58,826,911 Accumulated other comprehensive income 5,588,219 4,378,072 Total Shareholders' Equity 166,490,275 156,177,242 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $192,369,644 $185,273,946

[nevertheless]

Super Ergebnis für das 1Q - kein Zweifel.

Aber die Kapitalerhöhung über 13 Mio. neue Aktien (ca. 130 Mio USD) verstehe ich nicht ganz. Man hat doch rund 100 Mio. in der Kasse und einen positiven Cash-Flow. Die Erkärung für die Verwendung des Geldes ist ziemlich nichtssagend. Also, wenn der Kurs unter 9 USD geht, verabschiede ich mich vorsichtshalber (trotz guter Perspektiven).

[Raggamuffin]

June 13 (Reuters) - Pharmaceutical and nutraceutical company American Oriental Bioengineering Inc. (AOB.N: Quote, Profile , Research) signed a letter of intent to buy privately owned Changchun Xinan Pharmaceutical Group Co. Ltd. for nearly $30 million.

The deal is is expected to add to its operations within one year of closing, the company said in a statement.

internetseite dieser firma:

http://en.xayy.cn/newEbiz1/EbizPortalFG/portal/html/index.ht…

und hier wirds jetzt interessant. nennen wir die firma mal cxp. laut deren internetauftritt vertreiben sie 170 produkte in china und verkaufen auch nach russland vietnam und nordamerika. (also einfacherer einstieg für aob in diese märkte).
cxp ist noch relativ jung und hat 9 produktionslinien deren kapazitäten bitte selber nachlesen unter about us.
der umsatz von cxp soll laut internetauftritt bei 100. mio rmb liegen was ca. 13 mio usd entspricht und laut aob macht cxp seit 2006 gewinn.

also für mich ist diese aquisition um 30 mio usd ein schnäppchen da hier meiner meinung nach nur ca. das doppelte des 2007er umsatzes gezahlt wurde.

aob machte 2006 110 mio usd umsatz 30% steigerung haben sie sich vorgenommen operational und mittels aquisitionen

sind wir bei 143 mio usd -- 123 mio usd sinds mit der aquisition schon mal ohne operationelles wachstum und gleichbleibenden umsätzen von aob und cxp (halte ich mal da wir von china reden für sehr unwahrscheinlich).

die amis scheinen nicht so überzeugt davon aber ich denke das bleibt nicht die einzige aquisition heuer und da kommt noch was schliesslich hat aob 100 mio usd cash und macht ne kaperhöhung für weitere 130-150 mio usd macht insgesamt 230-250 mio usd minus 30 mio bleiben noch 200-230 mio usd.

da soll mir mal einer erzählen die machen damit nichts.

[Raggamuffin]

najajetzt haben wir ein double bottom und es wirkt das wird ein schönes großes W

hab bei 8,29 us$ nachgekauft und gezittert jetzt bin ich entspannt

[trueffelschweinchen]

momentan zieht es den Kurs ja ziemlich gen Süden...
Hat dafür jemand eine erklärung?

[Raggamuffin]

ich bin raus hier wirds meiner meinung nach noch tiefere kurse geben die investoren haben das vertrauen verloren. die kapitalerhöhung war aus ihrer sicht unnötig da ja bis jetzt nur ne company um 30 mio gekauft wurde und aob vorher schon 90 mio cash hatte.
erst wenn da noch ne übernahme kommt wird wieder gekauft.

aob ist ne chinesische firma und wird auch nochmal runterkrachen wenn der aktienmarkt in china kracht und das kommt auch in naher zukunft auf uns zu

[trueffelschweinchen]

Das sind doch prima Zahlen:

American Oriental Bioengineering Q2 Earnings Rise 67.2%; Guides Q3; Raises FY07 Revenue View [AOB]

8/8/2007 10:30:50 PM American Oriental Bioengineering, Inc. (AOB) reported second quarter net earnings of $9.67 million or $0.15 per share, up 67.2% from $5.83 million or $0.09 per share in the same quarter last year. Revenues for the quarter rose 48.7% to $33.91 million from $22.76 million in the comparable quarter a year-ago.

On average, two analysts polled by First Call/Thomson Financial expected earnings of $0.13 per share on revenues of $32.17 million for the second quarter.

Operating income for the second quarter increased 64.3% to $11.50 million from $7.01 million in the year ago quarter. Operating income as a percent of sales in the quarter rose 310 basis points to 33.9% from 30.8% in the preceding quarter last year.

Weighted-average common shares outstanding for the second quarter was 66.60 million, compared to 62.80 million in the prior year quarter.

For the first half, the company reported net income of $16.12 million or $0.24 per share, compared to income of $10.73 million or $0.17 per share in the previous year. Revenues for the period were $59.66 million, up from $41.81 million in the last year.

Operating income for the first six months was $19.42 million, compared to $13.83 million in the preceding year.

Weighted-average common shares outstanding for the first half was 66.48 million, compared to 62.06 million in the prior year period.

Looking forward for the third quarter of 2007, American Oriental expects earnings per share to be about $0.15, based on an estimated weighted average diluted share count of 76.0 million. The Street currently expects earnings of $0.16 per share for the quarter.

Revenue for the quarter is estimated to be about $42.0 million, while analysts expect revenues of $37.96 million for the quarter. Majority of the revenue growth outlook is coming from products that serve the OTC market, primarily the Jinji product portfolio. Third quarter revenue assumes about $1.0 million in revenue from the previously announced CCXA acquisition, assuming an August 2007 close.

For the fiscal 2007, the company anticipates earnings of $0.60 per share, based on an estimated weighted average diluted share count of 72.0 million. Analysts currently expect $0.63 earnings per share for the quarter.

The company raised its full year revenues outlook to about $158 million from prior guidance of about $146.0 million. The Street currently anticipates revenue of $149.28 million for the year. The revised revenue guidance includes about $8.0 million in revenues from CCXA and the newly announced Boke acquisition.

AOB closed Wednesday's regular trading at $8.28, up $0.48 or 6.15%, on a volume of 2.35 million shares on the NYSE. In after-hours trading, the stock gained 87 cents or 10.51%, traded at $9.15.

[nevertheless]

Antwort auf Beitrag Nr.: 29.632.669 von nevertheless am 04.06.07 17:27:59

Nach den Zahlen für das 2.Quartal und einer Anhebung der Prognosen bin ich wieder an Bord ...

Mittlerweile wird auch klar, dass mit der jüngsten Kapitalerhöhung über rund 130 Mio. USD weitere Akquisitionen finanziert werden. Mit Erwerb der Changchun Xinan Pharma hat man den ersten Schritt getan. Das Unternehmen hat in 2006 einen Umsatz von 9 Mio. USD erwirtschaftet und läuft profitabel. Wie profitabel wurde leider nicht gesagt. Der Kaufpreis von 28,5 Mio, scheint aber OK. Immerhin ist AOB auf Basis der geschätzten Umsätze für 2007 selbst mit einem Faktor von 5 bewertet.

Akquisitionsbedingt erwarte ich bei AOB einen Anstieg der Umsätze in 2007 um 46% auf 160 Mio. und das bei einer Gewinnmarge von knapp 29%. EPS also 0,60 USD. In 2008 könnten es einen weiteren Schub auf 235 Mio. USD Umsatz geben. Bei einer konstanten Gewinnmarge könnte der Gewinn je Aktie auf 0,80 USD ansteigen. KGV 17 in 2007 und 13 in 2008.

Auch Bilanzseitig ist alles im grünen Bereich. EK-Quote von 91%. Geschätzter Buchwert je Aktie in 2007: 3,70 USD, in 2008: 4,30 USD. Nicht zu unterschätzen ist die Zuverlässigkeit von AOB hinsichtlich der Vorlage seiner Geschäftszahlen, was man von anderen an US-Börsen notierten chinesischen Unternehmen (z.B. CXTI, SOEN) nicht behaupten kann.

Sollte sich das Wachstum im 3. und 4. Quartal im bisherigen Umfang fortsetzen und weitere Akquisitionen getätigt werden, sind in den kommenden Monaten durchaus Kurse zwischen 12 und 14 USD vorstellbar.

Auch unter charttechnischen Aspekten ist der Titel ein klarer Kauf, da er aus einer umgekehrten SKS Formation ausgebrochen ist. Stopkurs 8,25 USD.